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Summary 
The aim of the present thesis was to explore new approaches in the design and synthesis of 
new arene ruthenium species. This class of organometallic compounds has been the subject of 
much attention in the recent years due to their interesting properties in various fields, such as 
medicinal chemistry or supramolecular chemistry. In order to achieve this goal, this work was 
divided into two parts. 
In the first part, the synthesis of ruthenium complexes containing hydrazinyl-thiazole ligands 
was studied. These organic molecules have indeed proved to be highly active against some 
types of cancer; the strategy of this project was then to combine the activity of the organic 
ligand and that of the arene ruthenium core. The first series of complexes, where the ligands 
contained phenyl derivatives in their structure, was tested on human cervical and ovarian 
cancer cell lines. The results were overall good when compared to platinum anticancer 
compounds cisplatin and oxaliplatin, and some of the complexes showed selectivity in favor 
of cancerous cells over healthy ones. This led to an optimization of the structure of the 
complexes, as well as the synthesis of two other series of complexes, where the ligands 
contained pharmacophore aromatics moieties – phenothiazine and indole derivatives. 
In the second part, the design and synthesis of light responsive ruthenium assemblies was 
investigated. By using photoswitchable organic molecules as part of ruthenium metalla-
assemblies, the goal was to create ruthenium entities capable of existing in two different states, 
thus potentially providing a novel means to control the encapsulation and release of guest 
molecules. Several classes of molecules – azobenzene, anthracene, and dihydropyrene 
derivatives – were used in this project. Results indicated that semi-functional photoswitchable 
assemblies could be obtained with some of those molecules, and gave insight on the 
functioning of such assemblies. Several compounds synthesized in this project also have the 
potential to be used as vehicles for the transport of singlet oxygen, making them interesting 
both in medicinal and supramolecular chemistry. 
These results showed the versatility and relevance of arene ruthenium species in both the 
synthesis of a new family of anticancer complexes and the construction of novel light-
triggered supramolecular assemblies.  
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Chapter 1: Introduction 
 
1.1 History of Ruthenium 
Ruthenium is a transition metal discovered in 1844 by Karl Klaus, as part of the residues left 
after dissolving platinum ores in aqua regia.[1] Named after Ruthenia, the Latin name of 
Russia, ruthenium is the element 44 of Mendeleev’s periodic table, and is part of the Group 
VIII of this classification. It is a particularly rare element, its abundance in Earth’s crustal 
rocks being estimated at only 0.0001 ppm. In the metallic state, ruthenium is generally found 
in ores along with other “platinum” metals, and after being separated, it is isolated as a hard 
white metal (Figure 1). As a metal, the main use of ruthenium is the hardening of platinum 
and palladium; however, its rarity and therefore high cost of production, with only about 20 
tons produced each year,[2] make the industrial applications of ruthenium relatively limited. 
 
Figure 1: Ruthenium crystals 
 
Ruthenium shares a lot of properties with osmium, its neighbor in the periodic table, such as a 
high number – seven – of naturally occurring isotopes, and a wide range of available 
oxidation states, going from -II (d10) to +VIII (d0). This property is crucial and gives access to 
a variety of ruthenium compounds with different coordination modes and geometries. While 
the higher oxidation states are relatively unimportant in this regard and are mostly represented 
by oxides and halides,[3] oxidation states between 0 and +IV make for the most part of 
ruthenium coordination compounds, each electronic configuration of the metal being suited 
for different types of ligands. The diversity and tunability of compounds available make 
ruthenium a very interesting element and a promising candidate for traditional applications of 
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organometallic compounds, such as catalysis; but over the years, ruthenium has also proven to 
be a key element in other fields, as will be discussed here. 
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1.2 Uses of Ruthenium Organometallic Compounds 
1.2.1 In Catalysis 
Despite all of the interesting features described above, ruthenium organometallic chemistry is 
still fairly recent. Before the 1980s, ruthenium complexes were scarce and only used for the 
catalysis of organic reactions such as oxidations or hydrogenations. Since then, ruthenium 
chemistry has vastly expanded, and not only is ruthenium used as alternative to existent 
catalysts, but new organic reactions have also been developed using a ruthenium complex as 
catalyst. Nowadays, a large number of ruthenium species are used for a broad range of 
organic reactions, to the point that it is now of the same importance as palladium in the field 
of catalysis.[4] While it is not the goal of the present introduction to be comprehensive in that 
particular subject, some examples deserve to be mentioned. 
Hydrogenation is one of the most important and challenging reactions in organic chemistry; it 
gives access to a lot of interesting molecules and is widely used in the industry. Ruthenium 
dioxide RuO2 and the complex RuCl2(PPh3)3 were the first ruthenium compounds used as 
catalysts for the hydrogenation of anilines and olefins, respectively. Ever since, dozens of 
ruthenium complexes were designed for the hydrogenation of unsaturated compounds such as 
olefins, carbonyls, and aromatic compounds. Some of the most well-known are the Ru-
BINAP complexes, which are used in the enantioselective hydrogenation of alkenes.[5] 
Another area of catalysis where ruthenium has proven to shine is carbon-carbon bond 
formation. This kind of reaction is of paramount importance in chemistry, and while 
palladium definitely stands out thanks to its popular use in coupling reactions, the number of 
ruthenium compounds used to catalyze such reactions has risen significantly over the last 
decades. Among these reactions, the one which development was most influenced by 
ruthenium is the olefin metathesis. Since the early 1990s,[6] Grubbs and co-workers have 
designed several ruthenium-centered complexes designed towards metathesis catalysis, some 
of them which are now commercially available are traditionally used in different metathesis 
processes (Figure 2). 
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Figure 2: Grubbs Catalysts, 1st (left) and 2nd (right) generation 
 
1.2.2 In Dye-Sensitized Solar Cells 
Aside from catalysis, ruthenium also plays an important role in the preparation of dye-
sensitized solar cells (DSC). Polypyridine ruthenium complexes are found to be some of the 
best dyes to be used; Grätzel and co-workers have investigated many of them and reported 
them for the accessibility of their synthesis and for their spectral and redox properties.[7] 
Indeed, these complexes exhibit very strong charge transfer transitions, which lead to an 
efficient absorption of light. While this area can still be improved and the structure of the dyes 
refined, some of these ruthenium complexes have become standards and are now used in 
commercially available solar cells (Figure 3). 
              
Figure 3: Ruthenium-based N-3 (left) and N-719 (right) dyes 
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1.2.3 In Biology 
Ruthenium complexes are also extremely popular in medicinal chemistry, especially in the 
field of cancer treatment, with multiple compounds reported. However, they will not be 
discussed here, as it will be the topic of the introduction of Chapter 2 (see page 13). 
 
1.2.4 In Supramolecular Chemistry 
Supramolecular chemistry is a term coined by Jean-Marie Lehn and is defined as “the 
chemistry of molecular assemblies and of the intermolecular bond”.[8] It is a field located at 
the boundaries between organic chemistry and coordination chemistry, and focuses on 
assemblies held together by weak interactions such as metal-ligand bonds, Van der Waals 
forces, π-π interactions or hydrogen bonds. Supramolecular chemistry spawned several 
important concepts, such as self-assembly, molecular recognition and host-guest chemistry. 
These topics, as well as the influence of ruthenium in this field, will be discussed here. 
One of the first examples of molecular recognition is the encapsulation of metal cations inside 
crown ethers.[9] These complexes are stabilized thanks to the ion-dipole forces existing 
between the positively charged metal ion and the negatively charged oxygen atoms of the 
crown ether. By varying the length of the chain forming the crown, thus varying the size of 
the cavity of the cycle, different cations could be encapsulated, ranging from small alkali 
metal ions such as Li+ or Na+ to bigger species such as transition metal ions or lanthanide ions 
(Figure 4).[10] Interestingly, it was observed that the solubility of the metallic ions was 
modified when complexed to crown ethers, making them soluble in apolar solvents such as 
hydrocarbons. 
 
Figure 4: Schematic representation of the encapsulation of metallic cations inside crown ethers 
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These works on the concept of encapsulation of a “guest” molecule inside the cavity of a 
“host” molecule were only the beginning of what would become an essential component of 
supramolecular chemistry as a whole. Since then, many examples of host-guest systems have 
been reported in the literature. While some of them focus on organic molecules as hosts, such 
as cyclodextrins or calixarenes, attention was quickly given to metalla-assemblies capable of 
encapsulating a guest molecule. The first of this kind is a copper-based M2L2-type structure 
reported in 1984 by Maverick.[11] Because of the affinity of the metal towards nitrogen-
bonding ligands, this metalla-rectangle was able to encapsulate small diamines inside its 
cavity. A few years later, Fujita and co-workers reported the self-assembly of a platinum-
based supramolecular complex,[12] using ethylenediamine as a ligand “blocking” two cis 
positions of the coordination sphere of the metal, inducing the square shape of the resulting 
assembly in the presence of the linear linker 4,4’-bipyridine (Figure 5). As with Maverick’s 
work, this platinum complex was able to encapsulate small aromatic molecule, this time using 
π-stacking effect as host-guest interaction. The strong positive charge of the assembly makes 
it highly soluble in water, allowing – similarly to the case of crown ethers – the solubility of 
the hydrophobic guest molecule in aqueous media when encapsulated. 
 
Figure 5: X-ray crystal structure of Fujita’s M4L4 platinum square 
 
With its number of interesting features and properties, it was just a matter of time before 
ruthenium was investigated as the center of such supramolecular assemblies. In particular, 
arene ruthenium species were considered as the main building blocks. This type of 
compounds was first synthesized in 1967 by Winkhaus and Singer by reducing ruthenium 
(III) trichloride with 1,3-cyclohexadiene, even though the polymeric structure they proposed 
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was eventually found to be false.[13] The right structure of the compound formed was 
confirmed a few years later,[14] and consists in a dinuclear ruthenium (II) species, [(η6-
C6H6)Ru(μ2-Cl)Cl]2, where the two metal atoms are bridged together by two chlorine atoms 
(Scheme 1). 
 
Scheme 1: Synthesis of benzene ruthenium dichloride dimer 
 
Due to its easy synthesis and its excellent stability under atmospheric conditions, this 
compound became a key starting material for the synthesis of a whole library of ruthenium 
species suitable to make organometallic supramolecular assemblies. Indeed, the chlorine 
atoms of the dimer are particularly labile and easily removed, either to form monomeric, 
“half-sandwich” complexes; or to access other dinuclear species by using bridging 
tetradentate ligands such as dihydroxybenzoquinone derivatives. 
The former approach has been extensively developed by several groups, with many examples 
of metalla-cages based on arene mono-ruthenium species existing in the literature. Especially 
worth mentioning is the work of Severin regarding the design of ruthenium crown ether 
analogues.[15] Using arene ruthenium mononuclear complexes and polydentate anionic 
organic ligands, neutral metalla-crowns were synthesized. Like their organic counterparts, 
these assemblies exhibit host-guest properties, selectively binding alkali cations depending on 
the size of the assembly. The results obtained were highly interesting, and represent a 
milestone in this area of ruthenium supramolecular chemistry. 
The latter approach was mainly developed by our group, with the report of several dinuclear 
complexes obtained using para-cymene dinuclear ruthenium species [(η6-p-
MeC6H4Pr
i)Ru(μ2-Cl)Cl]2 as starting material. Like its benzene counterpart mentioned above, 
this dinuclear compound is obtained easily from ruthenium trichloride hydrate and α-
phellandrene,[16] and can be reacted with appropriate OO∩OO ligands to form different 
ruthenium dinuclear “clips”,[17] which size vary according to the spacer between the two 
ruthenium atoms, a feature very interesting to take into account when building supramolecular 
assemblies (Figure 6). These compounds are usually quantitatively obtained and are very easy 
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to handle; as they combine the hydrophilic nature of the metal and the hydrophobic nature of 
the aromatic moiety, they are generally soluble in polar and apolar solvents alike, such as 
water or dichloromethane. 
 
Figure 6: Ruthenium dinuclear clips with associated Ru-Ru lengths 
 
After removal of the terminal chlorine atoms with an appropriate reagent (silver 
trifluoromethanesulfonate is commonly used), these clips can be reacted with a molecule that 
will act as the “panel” of the cage, given that this molecule possesses a group with binding 
affinity for ruthenium – pyridyl derivatives are an excellent example of such molecules. This 
way, by varying the clip and panel used, it is possible to access a whole library of ruthenium 
metalla-cages with different sizes and geometries: depending on the molecule used as panel, 
the resulting cage can be of rectangular, prismatic or even cubic shape. 
This versatility is particularly interesting in a host-guest chemistry point of view, as the size 
of the cavity will greatly vary depending on the assembly. A lot of compounds can then be 
considered as guests, ranging from organic aromatic molecules such as pyrene or 
coronene,[18] to small metal complexes, such as the reported encapsulation of platinum and 
palladium complexes into a prismatic ruthenium cage (Figure 7).[19] 
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Figure 7: Typical hexanuclear ruthenium metalla-cage synthesized in our group, using 4-tpt (2,4,6-tris(4-
pyridyl)triazine) as panel, and examples of guest molecules 
 
In the last few years, this kind of supramolecular assembly was exploited in the context of 
medicinal chemistry. Indeed, one of the limitations when designing drugs is their solubility: 
since they are dispensed intravenously or orally, they need to be soluble in aqueous media, 
which is not always the case when molecules feature hydrophobic moieties such as aromatic 
rings. A way to overcome this issue is to encapsulate the target molecule inside the cavity of a 
metalla-assembly. As mentioned before, these ruthenium cages are mainly cationic and 
obtained as their trifluoromethanesulfonate salts, making them, as well as the guest molecule 
trapped into its hydrophobic cavity, highly soluble in water. This “Trojan horse” strategy was 
applied in the case of cancer treatment, where the ruthenium assembly acts as a vehicle able to 
transport its guest to the tumoral cells. This idea also revolves around the enhanced 
permeability and retention (EPR) effect. This concept states that large molecules tend to 
accumulate preferentially in cancerous tissue than in healthy ones. Using our ruthenium cages 
to transport it, the target molecule would then affect the tumor cells more selectively, leading 
to a better drug efficiency. This approach has been investigated in our group for the transport 
of photosensitizers in the case of photodynamic therapy, with very promising results.[20] 
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Nowadays, ruthenium is a key element when it comes to supramolecular chemistry. The 
accessibility of the starting materials and the diversity of compounds available make 
ruthenium a good building block to construct supramolecular assemblies with various sizes 
and shapes. While it is still a rising research topic, a large number of ruthenium assemblies 
have already been reported and have found applications in various fields, especially in 
medicinal chemistry. 
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1.3 Aim of this Work 
The present work is divided in two parts. The first part, which is discussed in Chapter 2, 
focuses on the synthesis of arene ruthenium complexes containing hydrazine-thiazolo ligands, 
and the investigation of their properties as antitumor agents. The aim of this project is to 
combine the biological activity of the ruthenium moiety with that of the organic part, in order 
to obtain compounds with a high activity against tumoral cells. Their synthesis, 
characterization and biological activity will be discussed. 
The second part, discussed in Chapter 3, presents the concept of light-responsive ruthenium 
assemblies. Organic molecules that undergo structural changes upon light irradiation are 
called “photoswitches”. The goal is to synthesize such molecules and include them as part of 
a ruthenium assembly. By doing so, it would be possible to create a structure capable of 
transporting a molecule inside its cavity, using host-guest interactions, and be able to trigger 
the light-responsive element of the assembly. This would then induce a change in the structure 
of the whole assembly, disrupting the host-guest interactions, thus providing a novel means to 
control the release of the guest molecule. 
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Chapter 2: Synthesis, Characterization and Anticancer Activity of 
Hydrazinyl-Thiazole Arene Ruthenium Complexes 
 
2.1 Introduction 
Cancer is one of the leading causes of mortality worldwide, with 14 million new cases and 
over 8 million cancer-related deaths reported in 2012, and it is expected that these numbers 
will keep rising during the next decades. Cancer is a result of an abnormal and uncontrolled 
cell growth, leading to the formation of tumors which can then spread throughout the body. 
The causes of cancer are multiple, though most of them result from environmental or lifestyle 
factors and tend to occur more frequently in developed countries.[21] Nowadays, several 
methods are used to treat cancers, the most common being surgery, radiotherapy and 
chemotherapy; the latter will be discussed here. 
Chemotherapy is, by definition, the use of chemical compounds to treat diseases, even though 
its meaning is now narrowed down to the treatment of cancer only. Its emergence occurred 
during World War I, when the infamous mustard gas was found to be a potential suppressor of 
blood cells production, a property that could be used to stop the growth of tumoral cells. This 
led to the discovery and investigation of nitrogen mustard molecules, such as 
chlormethine.[22] These compounds indeed proved to be cytotoxic, and were the first 
alkylating agents used in chemotherapy, named after their ability to bind to DNA. Other 
alkylating agents were later designed (Figure 8), such as chlorambucil (marketed Leukeran), 
an aromatic mustard used mainly against lymphocytic leukemia, which presented less side 
effects and also had the advantage of being taken orally rather than intravenously.[23] 
Different groups of molecules were also investigated for their anticancer properties, each 
having their own mechanism of action. Antimetabolites, for instance, are chemicals able to 
interfere with DNA and RNA production, thus limiting the division of tumoral cells. Many of 
them are now used to treat various types of cancer, an example being gemcitabine (marketed 
Gemzar).[24] 
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Figure 8: Alkylating agents chlormethine and chlorambucil, and antimetabolite gemcitabine 
 
Metal based drugs have also been investigated in this field. The first metal-centered 
compound to be used in chemotherapy was cis-diamminedichloroplatinum (II), more 
commonly called cisplatin. This platinum complex was first discovered in the 19th century, 
but its anticancer properties were only found in 1965.[25] Due to its high activity against 
cancer cells, cisplatin was rapidly approved for clinical use. Since then, it is used against 
many types of cancer, such as bladder or testicular cancers, with very good cure rates for 
some of them. As a result, researchers have focused a lot on platinum complexes designed 
towards cancer treatment; besides cisplatin, two of its analogues are now used in clinics 
worldwide (Figure 9). 
 
Figure 9: Clinically approved platinum complexes used in chemotherapy  
 
Chemotherapy, while being the most widely used technique to cure cancer, has several 
limitations. The main one is the lack of selectivity of the drug, which also often kills healthy 
cells, and thus leads to undesirable side effects (hair loss, fatigue, nausea, etc.). The resistance 
of cancerous cells to drugs is also a major problem, as it is the case with cisplatin. Its 
inefficiency on platinum-resistant tumors is a huge disadvantage, which led to the search for 
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alternative agents to resolve this drawback. Among these candidates, ruthenium has 
undoubtedly stood out. 
Over the last few decades, many examples of ruthenium compounds have been reported, some 
of which are already into clinical trials, such as the well-known complexes [imiH]trans-
[Ru(N-imi)(S-dmso)Cl4] (NAMI-A),[26] and [Na]trans-[Ru(N-ind)2Cl4] (NKP-1339)[27] 
(Figure 10). These ruthenium (III) complexes, which have shown very promising results, are 
in fact prodrugs: they are activated in the reductive tumor environment, generating ruthenium 
(II) species which appeared to be the actual antitumoral agents.  
 
Figure 10: Ruthenium (III) anticancer complexes NAMI-A and NKP-1339 
 
Ever since this discovery, several groups have developed the strategy of directly using 
ruthenium (II) complexes when designing anticancer drugs. This led to the emergence of 
interesting arene ruthenium (II) compounds, such as those reported by Dyson[28] or 
Sadler[29] (Figure 11). Those complexes present some advantages over cisplatin, namely 
their activity against cisplatin-resistant cancerous cell lines, and their higher selectivity for 
cancerous over healthy cells, leading to reduced side effects. 
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Figure 11: Arene ruthenium (II) anticancer complexes RAPTA-C and RM175 
 
Since then, this field of research has expanded quite significantly, and the number of 
ruthenium complexes designed towards anticancer applications has exponentially risen over 
the years (Figure 12). Many researchers have also designed ruthenium-centered complexes 
bearing biologically active organic ligands, with the goal of taking advantage of the properties 
of both moieties. Hydrazinyl-thiazole compounds, for example, have received much attention 
in recent years due to the identification in the 1990s of several thiazole compounds showing 
antitumor activity.[30] These molecules can be easily synthesized and functionalized with 
various chemical groups, allowing a fine-tuning of the structures in order to achieve the 
desired biological properties,[31] and can also act as a N,N’ chelating ligand towards 
transition metals such as ruthenium. 
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Figure 12: Number of publications per year regarding “anticancer ruthenium complexes” from 1990 to 2015 
 
In this work, a p-cymene ruthenium unit and hydrazinyl-thiazole ligands were combined to 
generate series of organometallic compounds with significant antitumor activity, taking 
advantage of the synthetic versatility of thiazole derivatives and the promising biological 
activity of ruthenium complexes. 
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2.2 Phenyl Derivatives 
2.2.1 General 
Thiazoles and their derivatives are compounds which usually exhibit many biological 
properties, such as antimicrobial, antiviral or anticancerous activities. The different 
hydrazinyl-thiazole compounds used in this work were prepared by co-workers at the 
Universtiy of Cluj, Romania, using the synthetic route showed in Scheme 2. 
 
Scheme 2: Synthesis of hydrazinyl-thiazole derivatives 
 
The first step consists in the condensation of an aromatic aldehyde with thiosemicarbazide; 
the desired products are then obtained thanks to a Hantzsch cyclization reaction as a second 
step. These reactions are fairly simple and quite efficient in terms of yield and purity, and the 
large choice of available aromatic aldehydes (for the first step) and α-halocarbonyls (for the 
second step) allow for a very diverse library of final compounds. The hydrazinyl-thiazole 
compounds obtained this way can act as bidentate ligands: both azomethine (CH=N) and 
thiazole nitrogen atoms are electronically available and geometrically well arranged for a 
coordination bond towards ruthenium (II) species. In this section, the focus is placed on 
phenyl-based (i.e. where R3 is a phenyl derivative) hydrazinyl-thiazole compounds and their 
corresponding ruthenium complexes. 
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2.2.2 Results, Discussion and Structure Optimization 
A series of monocationic ruthenium complexes (1-16) containing hydrazinyl-thiazole 
bidentate ligands (L1-L16) was prepared (Scheme 3, Table 1). The synthesis of the 
complexes was realized by two methods: (A) a conventional synthetic method involving one 
equivalent of the ruthenium dimer (η6-p-cymene)2Ru2Cl4 and two equivalents of the 
hydrazinyl-thiazole derivatives (L1-L16) in methanol at room temperature for 10 hours; and 
(B) a microwave-assisted synthetic method, whose optimal reaction conditions were 
established after several experiments, varying the solvent (methanol, acetonitrile and 
dichloromethane), the temperature (40 °C, 60 °C, 82 °C and 100 °C) and the reaction time 
(0.5 h, 1 h, 1.5 h and 2 h). The best yields for the complexes were obtained after 0.5 h of 
microwave irradiation at 60 °C and using dichloromethane as solvent. The two alternative 
synthetic methods are comparable for the resulting yield (50-80%), but the microwave-
assisted method demands a shorter reaction time (30 minutes versus 10 hours). In order to 
make it greener, the synthesis was tried using water instead of an organic solvent. 
Unfortunately, in water, the complexes could only be recovered in traces. 
 
Scheme 3: Synthesis of complexes 1-16 (R1, R2 and R3 functional groups are given in Table 1) 
 
 
  R1 R2 R3  
R1 R2 R3 
L1 Me H Ph L9 Me H 4-MeO-C6H4 
L2 Ph H Ph L10 Ph H 4-MeO-C6H4 
L3 Me COMe Ph L11 Me COOEt 4-MeO-C6H4 
L4 CH2COOEt H 2,4-Cl2-C6H3 L12 Me COMe 4-MeO-C6H4 
L5 Me COMe 2,4-Cl2-C6H3 L13 Me H 3-Cl-C6H4 
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L6 Me COOEt 2,4-Cl2-C6H3 L14 Me COMe 3-Cl-C6H4 
L7 Me H 4-HO-C6H4 L15 Ph H 3-Cl-C6H4 
L8 Ph H 4-HO-C6H4 L16 Me COOEt 3-Cl-C6H4 
 
Table 1: Identification of the functional groups R1-R3 attached to the hydrazinyl-thiazole compounds L1-L16 
 
All complexes were isolated as their chloride salts, and were fully characterized by 1H NMR, 
mass spectrometry, IR spectroscopy, elemental analysis, and for 12 by a single-crystal X-ray 
structure analysis. No attempt to separate the cationic enantiomers was performed, and the 
chiral-at-metal complexes were isolated and used as racemic mixtures. All complexes are 
soluble in most organic solvents; they are stable in D2O and DMSO solutions as well as in 
biological media (aqueous solution containing RPMI 1640 medium with 5% fetal calf serum, 
glutamine, and antibiotics), showing no decomplexation of the hydrazinyl-thiazole ligands. 
The 1H NMR spectra of all complexes show, in addition to the signals of the p-cymene ring, 
the characteristic signals of the ligand at higher chemical shifts related to its free form because 
of the deshielding effect produced by the arene ruthenium unit. Typical signals for the ligands 
after complexation are a singlet at around 9 ppm associated with the proton of the azomethine 
moiety (CH=N) and the proton from the hydrazine moiety (N-NH), which is the most 
deshielded one, appearing as a broad singlet at around 15 ppm (in some cases the signal is not 
observed due to the deuterium exchange). In the case of the complexes where R2 = H, the 
corresponding proton of the thiazole ring is observed as a singlet at around 6.5 ppm. The mass 
spectra of all complexes conveniently show, in positive mode, a peak corresponding to the 
mass of the cation without its chloride counteranion, sometimes along with other fragment 
peaks (Figure 13). IR spectra of all complexes mainly show bands corresponding to the C-H 
bond stretch of aromatics (~2950 cm-1), and more specific bands depending on R1-R3 groups, 
such as the O-H stretch of phenol derivatives (~3400 cm-1) or the C=O stretch bands (~1600 
cm-1) when carbonyls are present in the structure. 
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Figure 13: 1H NMR spectrum of complex 1 in CDCl3, with annotated characteristic signals (top); and mass 
spectrum of 1 with peaks attribution (bottom) 
[M]+ 
[M-HCl]+ 
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Crystals suitable for a single-crystal X-ray structure analysis were obtained for [(η6-p-
cymene)Ru(L12)Cl]Cl by slow evaporation of a solution of the complex in methanol. The 
molecular structure of the cation is presented in Figure 14, together with selected geometrical 
parameters. In complex 12, the ruthenium center shows a typical pseudotetrahedral geometry 
with the hydrazinyl-thiazole ligand being N,N’ coordinated. The Ru-N bond distances are 
2.090(6) (thiazole) and 2.123(6) Å (hydrazine), and these values are similar to those found in 
analogous N,N’-coordinated pyridyl-thiazole arene ruthenium complexes.[32] In the solid 
state, an angle of 34.6(3)° is observed between the plane formed by the hydrazinyl-thiazole 
unit and the plane of the methoxyphenyl group. 
 
Figure 14: ORTEP drawing of complex 12 at 35% probability level, with hydrogen atoms being omitted for 
clarity. Selected bond lengths (Å) and angles (°): Ru(1)-Cl(1) 2.408(2), Ru(1)-N(1) 2.090(6), Ru(1)-N(3) 
2.123(6), N(2)-N(3) 1.396(7), and N(3)-C(17) 1.299(8); Cl(1)-Ru(1)-N(1) 85.61(15), Cl(1)-Ru(1)-N(3) 
90.04(15), N(1)-Ru(1)-N(3) 76.2(2), N(1)-C(16)-N(2) 120.5(6), C(16)-N(1)-Ru(1) 112.1(4), C(14)-N(1)-Ru(1) 
133.8(5), C(17)-N(3)-Ru(1) 133.7(5), N(2)-N(3)-Ru(1) 111.1(4), N(2)-N(3)-C(17) 114.2(6), and C(13)-S(1)-
C(16) 88.2(3) 
 
Complexes 1 to 16 were tested in vitro for their antiproliferative activity on four cell lines: 
HeLa (human cervical cancer cells), A2780 (human ovarian cancer cells), A2780cisR 
(cisplatin-resistant human ovarian cancer cells) and HFL-1 (noncancer cells, human 
fibroblast). As shown in Table 2, IC50 values were used to determine the antiproliferative 
activity of the complexes. Moreover, the calculated partition coefficients (log P) of the 
hydrazinyl-thiazole compounds L1-L16 together with their IC50 values on HeLa cells[31] are 
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presented in Table 3, thus giving an approximation of the lipophilicity and cytotoxicity of the 
ligands. Cisplatin and oxaliplatin were used as controls, and their IC50 values are also reported 
(Table 2). 
  IC50 (μM) 
  HeLa A2780 A2780cisR HFL-1 
cisplatin 20.10 ± 0.02 11.30 ± 0.02 41.13 ± 1.24 9.50 ± 0.02 
oxaliplatin 12.72 ± 0.02 10.10 ± 0.03 16.57 ± 0.02 13.53 ± 0.02 
1 7.42 ± 0.01 9.65 ± 0.01 12.95 ± 0.04 18.48 ± 0.02 
2 2.55 ± 0.02 2.49 ± 0.02 0.93 ± 0.02 6.27 ± 0.01 
3 11.42 ± 0.02 6.99 ± 0.02 2.08 ± 0.03 6.43 ± 0.02 
4 3.65 ± 0.03 12.21 ± 0.03 12.62 ± 0.01 181 ± 0.89 
5 7.98 ± 0.01 50.08 ± 0.03 55.58 ± 0.03 47.33 ± 0.32 
6 0.84 ± 0.25 2.86 ± 0.01 6.06 ± 0.02 4.52 ± 0.01 
7 19.40 ± 0.03 6.13 ± 0.25 6.19 ± 0.01 49.40 ± 0.31 
8 6.87 ± 0.23 5.25 ± 0.03 4.24 ± 0.01 7.30 ± 0.03 
9 7.95 ± 0.03 6.97 ± 0.33 6.80 ± 0.05 6.47 ± 0.23 
10 2.26 ± 0.03 5.12 ± 0.03 1.33 ± 0.02 13.88 ± 0.03 
11 5.66 ± 0.01 9.47 ± 0.03 3.14 ± 0.01 4.27 ± 0.03 
12 7.88 ± 0.01 4.54 ± 0.01 2.25 ± 0.03 3.84 ± 0.01 
13 11.15 ± 0.01 6.13 ± 0.02 2.14 ± 0.05 6.32 ± 0.02 
14 2.69 ± 0.01 2.26 ± 0.03 2.14 ± 0.04 36.61 ± 0.48 
15 6.81 ± 0.03 7.70 ± 0.12 2.77 ± 0.01 13.69 ± 0.01 
16 1.72 ± 0.01 3.75 ± 0.02 3.76 ± 0.03 2.81 ± 0.03 
 
Table 2: Cytotoxic activity of complexes 1-16 in HeLa, A2780, A2780cisR and HFL-1 cell lines 
 
The results obtained on the three tumor cell lines (HeLa, A2780 and A2780cisR) show a 
promising profile for the antiproliferative activity of all complexes, most of them having a 
cytotoxic activity at concentrations significantly lower than that of cisplatin and oxaliplatin. 
Moreover, by comparing the antiproliferative effect produced by the complexes on the tumor 
cell lines A2780 and A2780cisR, it can be noticed that at almost the same concentrations, a 
similar effect is observed on both cell lines, suggesting a mode of action different from that of 
cisplatin. By analyzing the effect of the treatment with the complexes on the normal 
fibroblasts cell line HFL-1, a significant reduction of cytotoxicity can be noticed for 
complexes 4 (IC50 = 181 μM) and 14 (IC50 = 36.6 μM). When comparing the cytotoxic effect 
produced by these two complexes on all the tumor cell lines, a selectivity in favor of the 
noncancerous cell line can be observed, i.e. a cytotoxic effect upon normal fibroblasts 15 
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times lower than upon tumoral cells. Moreover, the activities of the hydrazinyl-thiazole 
compounds L4 and L14 on HeLa cells are very low (>100 μM), confirming the beneficial 
effect of complexation to arene ruthenium units (Tables 2 and 3). 
  log P IC50 (μM) 
L1 3.1 ± 0.6 11.4 ± 0.005 
L2 4.4 ± 0.6 >100 
L3 2.6 ± 0.8 64.87 ± 0.005 
L4 4.4 ± 0.6 >100 
L5 4.0 ± 0.9 >100 
L6 4.6 ± 0.9 >100 
L7 2.9 ± 0.6 25.59 ± 0.010 
L8 4.2 ± 0.6 20.04 ± 0.019 
L9 3.3 ± 0.6 >100 
L10 4.6 ± 0.6 11.1 ± 0.009 
L11 3.8 ± 0.9 >100 
L12 2.7 ± 0.9 >100 
L13 3.9 ± 0.6 57.53 ± 0.011 
L14 3.4 ± 0.9 >100 
L15 5.2 ± 0.6 >100 
L16 4.4 ± 0.9 >100 
 
Table 3: Cytotoxic activity of compounds L1-L16 in HeLa cells and calculated partition coefficients 
 
Such variations in the activity appear to be dependent on some minor modifications in the 
molecular structure of the complexes, thus revealing some interesting trends. Indeed, the 
presence of electron-withdrawing groups (chloro and dichloro) on the phenyl ring of R3 leads 
to a higher antiproliferative effect on the cancerous cell lines. The presence of a more 
hydrophobic substituent (phenyl) at the R1 position of the thiazole ring also increases the 
antiproliferative activity, with the exception of 13 (methyl) and 15 (phenyl) which show a 
higher activity only on the HeLa cell line. However, the nature of the R2 group (H, COMe and 
COOEt) appears to have a less predictable effect. In complexes 13, 14 and 16 where only R3 
varied, the cytotoxicity of the complexes is comparable, while between complexes 5 and 6 the 
COMe derivative is significantly less cytotoxic than the COOEt analogue. 
Moreover, when looking at the log P values of L1-L16 in conjunction with their IC50 values 
on HeLa cells, it appears that the lipophilicity of the ligands does not correlate with the 
activity. Therefore, it can be deduced from these results that the functionalization of the 
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ligands can be further explored in order to optimize the biological activity of these 
hydrazinyl-thiazole arene ruthenium complexes. 
Following these results, hydrazinyl-thiazole ruthenium complexes 17 and 18 were synthesized 
using the same procedure as described previously. Both include a phenyl ring as the R1 
substituent and a chlorinated phenyl ring as the R3 substituent (Figure 15). 
 
Figure 15: Complexes 17 and 18 
 
As for the previous series, these two complexes were isolated as their chloride salts and were 
successfully characterized by 1H NMR spectroscopy, mass spectrometry, IR spectroscopy and 
elemental analysis. They share the same spectroscopic features with the other complexes, 
such as the typical 1H NMR signals and MS peaks. Pure samples of 17 and 18 were sent to the 
Iuliu Hatieganu University of Medicine and Pharmacy in Cluj, Romania, for the investigation 
of their biological properties, and are currently undergoing cytotoxic activity tests on the same 
cell lines – both cancerous and healthy – as described above. 
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2.3 Phenothiazine Derivatives 
2.3.1 General 
Phenothiazine is an aromatic tricyclic compound containing both nitrogen and sulfur atoms, 
first synthesized in 1883 via the reaction of diphenylamine with sulfur. Phenothiazine later 
proved to be a parent molecule of a lot of pharmaceutically interesting compounds. One of the 
first and most well-known of such phenothiazine derivatives is methylene blue (Figure 16), 
which presents a lot of medical uses.[33] 
 
Figure 16: Phenothiazine (left) and methylene blue (right) 
 
In recent years, some phenothiazine derivatives have been reported for their activity against 
human ovarian cancer cells,[34] similar to those used in the previous part of this work, while 
others have proved to be efficient on multidrug resistant cancerous cells,[35] making 
phenothiazine a promising building block in modern drug design. 
In this part of this work, hydrazinyl-thiazole compounds bearing a N-ethyl phenothiazine ring 
are used as ligands for a new series of biologically active ruthenium complexes. 
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2.3.2 Results and Discussion 
Four monocationic ruthenium complexes (19-22) containing phenothiazine-based hydrazinyl-
thiazole ligands were synthesized using procedure A described previously (Figure 17).
 
Figure 17 : Complexes 19 to 22 
 
These complexes were isolated as their chloride salts in good yields, comparable to those 
obtained for the first series of complexes. They were characterized by 1H NMR spectroscopy, 
mass spectrometry, IR spectroscopy and elemental analysis. The proton NMR spectra show 
the same characteristic signals for the azomethine moiety and for the thiazole ring when R2 = 
H (19 and 21). In addition, the typical triplet and quadruplet signals associated to the N-ethyl 
group can be observed, as emphasized in Figure 18. 
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Figure 18: 1H NMR spectrum of complex 20 in CDCl3 with annotated characteristic signals 
 
Since phenothiazine-type compounds are known to exhibit strong fluorescence emission,[38] 
experiments were conducted in order to see if this feature is still present in ruthenium-
phenothiazine complexes. Emission spectra were recorded for solutions of N-ethyl-
phenothiazine, ligand L22 and complex 22 in dichloromethane (c = 1.0 x 10-6 mol·L-1) with 
an excitation wavelength of 245 nm, determined by UV-visible absorption spectroscopy 
(Figure 19). 
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Figure 19: Fluorescence spectra of N-ethyl-PTZ, L22 and 22 in CH2Cl2, with λex = 245 nm 
 
The results of this study show that both L22 and 22 exhibit a diminution of about 25% of the 
emission intensity compared to free N-ethyl-PTZ, likely due to the presence of the hydrazinyl-
thiazole moiety, disturbing the electronic environment of the phenothiazine group and thus 
changing its spectroscopic properties. However, ligand L22 and ruthenium complex 22 
present almost exactly the same emission spectrum, showing that the arene-ruthenium core 
does not hinder the fluorescence properties of the ligand. This feature is very important, as it 
represents an easy way to identify and track phenothiazine-containing ruthenium anticancer 
complexes. 
Even though they bear an aromatic tricyclic moiety, all four complexes have a very similar 
solubility to that of the first series: they remain soluble in polar solvents, and proved to be 
very stable in solution. As with 17 and 18, samples of complexes 19-22 were sent to the Iuliu 
Hatieganu University of Medicine and Pharmacy in Cluj, Romania, to perform the 
cytotoxicity tests on the same cell lines as previously described. These results should provide 
information on whether the biological properties of the phenothiazine group carry on in the 
complexes, and could lead – as was the case in the first series of complexes – to an 
optimization of the structure of the complexes in order to achieve the best possible activity. 
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2.4 Indole Derivatives 
2.4.1 General 
Indoles are aromatic bicyclic compounds, consisting of a benzene ring fused to a nitrogen-
containing pyrrole ring. Indoles are natural compounds, mostly found in plants and in green 
vegetables. This class of molecules has been known to be phytonutrient, i.e. to present health-
protecting properties. More recently, the intake of vegetables containing indoles has been 
associated with the reduction of the risk of several cancers.[36] Indole-3-carbinol and its 
dimer 3,3’-diindolylmethane, for example (Figure 20), have shown to induce apoptosis in 
several human cancerous cell lines.[37] 
 
Figure 20: Indole and its derivatives indole-3-carbinol and 3,3’-diindolylmethane 
 
In the last part of this work, hydrazinyl-thiazole ligands containing an indole moiety are used 
for the synthesis of ruthenium complexes, with the goal of combining the biological 
properties of the organic thiazole and indole groups and that of the metallic ruthenium center. 
 
2.4.2 Results and Discussion 
A series of nine ruthenium complexes (23-31) bearing indole hydrazinyl-thiazole ligands was 
synthesized using procedure A as described before. 
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  R1 R2 R3 log P 
L23 Me H H 3.1 ± 0.8 
L24 Me COMe H 2.5 ± 1.1 
L25 Ph H H 4.4 ± 0.9 
L26 CH2COOEt H H 2.9 ± 0.9 
L27 Me H COMe 3.1 ± 0.9 
L28 Ph H COMe 4.4 ± 0.9 
L29 Me COMe COMe 2.5 ± 1.2 
L30 Me COOEt COMe 3.6 ± 1.2 
L31 CH2COOEt H COMe 2.9 ± 0.9 
 
Table 4: Identification of the functional groups R1-R3 attached to the hydrazinyl-thiazole compounds L23-L31 
and calculated partition coefficients 
 
Complexes 23-31 were isolated as their chloride salts and were characterized by 1H NMR 
spectroscopy, mass spectrometry, IR spectroscopy and elemental analysis. In addition to the 
usual characteristic signals of the hydrazinyl-thiazole moiety, the N-acetyl group present in 
complexes 27 to 31 can be easily noticed both on proton NMR and IR spectra – especially in 
complexes 27 and 28, where it is the only carbonyl group in the structure. All complexes, 
including those bearing hydrophobic substituents and thus having high partition coefficients, 
show good solubility in water, a crucial property when considering medicinal applications. 
Compounds 23-31 were submitted for biological testing, still using the same human cancerous 
cell lines in order to evaluate their cytotoxicity, with results pending. As for the previous 
series of complexes, good anticancer activity is expected thanks to the combination of the 
ruthenium core and the indole-containing organic pharmacophore. 
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2.5 Conclusion 
Three series of novel monocationic ruthenium complexes containing hydrazinyl-thiazole 
ligands were synthesized and characterized. The complexes forming the first series (1-16) – 
phenyl derivatives – were submitted to biological tests to investigate their anticancer 
properties against human ovarian and cervical cancer cells. Results were overall good, with 
most complexes exhibiting better cytotoxicity than clinically used compounds cisplatin and 
oxaliplatin. Moreover, in the case of two complexes (4 and 14), a selectivity in favor of cancer 
cells over healthy cells was observed. This later on led to the synthesis of complexes 17 and 
18, which structures were designed according to the previously obtained results, by choosing 
R1-R3 groups that seemed to contribute to both cytotoxicity and selectivity. These two 
complexes are currently undergoing biological tests. 
Two other series of hydrazinyl-thiazole ruthenium complexes were then synthesized, using 
phenothiazine and indole moieties, respectively, as part of the structure of the ligands. Indeed, 
these classes of molecules present some biological activity on their own; the goal of this 
project was to exploit this feature in order to further bring out the synergy between the 
ruthenium core and the organic ligand. This resulted in the synthesis and characterization of 
thirteen new complexes which are now being tested for their antiproliferative activity. 
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Chapter 3: Design and Synthesis of Light Responsive Arene 
Ruthenium Assemblies 
 
3.1 Introduction 
Molecular switches are, by definition, molecular systems consisting of at least two different 
states, connected to each other through a reversible transformation activated by an external 
stimulus. Such systems have been the subject of much attention over the years, as they present 
a wide range of potential applications, from optical displays to molecular electronics. Indeed, 
having access to two different states in a molecule – or a molecular assembly – allows one to 
perform binary logic at a molecular level, which can prove very useful, in particular if each 
state can be isolated and “gated” behind a particular stimulus; this concept is illustrated in 
Scheme 4.[39] 
 
Scheme 4: Sketched concept of a molecular switch 
 
Molecular switches can be very diverse in their mode of operation, whether regarding the type 
of transformation involved or the stimulus applied to perform said transformation. While 
staying concise, the present introduction will summarize examples of recent and popular 
molecular switch systems, especially in the field of organometallic chemistry. 
Redox reactions have been thoroughly investigated in that matter, thanks to the large amount 
of different systems available and their reversible nature.[40] Moreover, electrons represent 
an easily accessible and relatively mild stimulus to trigger a molecular switch. Among all 
existing examples, the redox system reported by Yano and co-workers is a particularly 
interesting one (Scheme 5).[41] 
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Scheme 5: Example of a redox-triggered molecular switch 
 
The dithiol compound pictured above, which structure resembles that of crown ethers, acts as 
a receptor of small cations such as Ag+ thanks to its cavity. Upon oxidation with hydrogen 
peroxide, a disulfide bridge is formed between the two sulfur atoms, thus blocking the cavity 
of the molecule and making the complexation of a cation impossible. The disulfide compound 
can then be reduced using sodium borohydride, reverting back to the open, crown ether-like 
dithiol form. This redox reaction gives access to a switchable host-guest system, a feature 
very interesting for many different applications, as will be discussed in this chapter. 
Molecular switching does not necessarily involve structure changing, though; the difference 
between the two states of a switch can be about properties. Staying in the field of molecular 
recognition and host-guest chemistry, examples have been reported of organic compounds 
having their properties altered when complexed to a guest molecule. It is the case for the 
system shown in Scheme 6: the anthracene moiety of the molecule has its luminescence 
quenched due to the presence of the lone electron pair of the nearby nitrogen atoms. The 
luminescence is recovered either upon protonation of these nitrogen atoms, or upon 
complexation of a metallic ion such as Zn2+, the organic molecule acting as a bidentate ligand 
towards the transition metal.[42] The original state can then be recovered by using a base or 
by removing the metal cation. This example, by combining host-guest chemistry and 
luminescence on-off switching, makes for a very nice chemical sensor, and is merely one of 
many similar systems. 
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Scheme 6: Example of a complexation-triggered molecular switch 
 
A lot of other molecular switches have recently been reported in the literature, using various 
stimuli to operate, such as pressure,[43] temperature,[44] or variation of the pH.[45] However, 
one of the most interesting and widely used type of switchable systems, and the main topic of 
the current chapter, is light-triggered molecular switches. Indeed, light is a convenient and 
powerful tool to use in such a context, especially considering the large number of functional 
groups that undergo structural changes when irradiated by light. 
Among this huge photochemical library of compounds available, a few classes of molecules 
have stood out and have proved to be promising candidates for use as molecular switches. 
One of them is diarylethenes. These molecules, which have been extensively studied by Irie, 
can undergo a reversible cyclization reaction using the right wavelengths (Scheme 7).[46] 
Diarylethenes present some interesting features, such as the tunability of their structure (and 
therefore of their absorption properties), and the thermal stability of its two forms, allowing 
for a light-only activation of the switch under the right conditions. Numerous applications of 
the switchable property of diarylethenes have been reported in the last few years, including 
some, interestingly, in the field of host-guest chemistry.[47] 
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Scheme 7: Example of a diarylethene photoswitch 
 
 
Many other photoswitchable molecules exist, some of which will be discussed in this chapter. 
Among them, azobenzenes[48] and spiropyrans,[49] for example, have seen interesting 
applications in organometallic chemistry, thanks to their unique photochromic properties. The 
goal of the present project is to use such photoswitchable moieties and include them as part of 
ruthenium metalla-assemblies. Since the release of guest molecules from inside the cavity of a 
ruthenium cage has so far mainly been controlled by varying the size of the cavity[50] or by 
uncontrolled breaking of the assembly,[51] the focus of our group in the last few years has 
been to find novel means to control the guest release. The synthesis of light-triggered 
assemblies would represent a step in the achievement of this purpose. This could particularly 
be of high interest for drug delivery systems (Scheme 8), as light has proven to be a 
convenient and mild tool to use for medicinal applications. 
 
Scheme 8: Schematic representation of the concept of guest release from a light-triggered ruthenium assembly 
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3.2 Ruthenium-Azopyridine Assemblies 
3.2.1 General 
Azobenzene-type compounds are molecules consisting of a nitrogen-nitrogen double bond, 
each nitrogen being linked to an aryl group. Azobenzene itself was first reported in 1834 by 
Mitscherlich,[52] although its photochemical properties were only discovered more than a 
century later.[53] Azobenzene can undergo isomerization from its trans (E) form – the most 
stable one – to its cis (Z) form – less stable – using UV light. Although the reverse 
isomerization tends to occur thermally in the dark, the trans form can be selectively recovered 
using irradiation with visible blue light (Scheme 9). 
 
Scheme 9: Photochemical isomerization of azobenzene 
 
This transformation induces a drastic change in the geometry of the molecule: the distance 
between the two atoms in position 4 of the aromatic rings decreases from 9 Å to 5.5 Å; and 
unlike the trans isomer, the cis one is not flat: the aromatic rings electronically repulse each 
other, creating an angular geometry.[54] The switching ability of azobenzenes has been 
exploited in many different fields over the years, for instance in biology in order to control 
some biological processes using irradiation.[55] Interesting examples of host-guest chemistry 
have also been reported,[56] taking advantage of the isomerization feature of the azo moiety 
to design functional switches based on molecular recognition, such as the one shown in 
Scheme 10.[57] 
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Scheme 10: “Molecular scissors” using the isomerization of azobenzene to control the encapsulation of a 
Fe (II) ion 
 
In this work, azopyridine is used as an azobenzene derivative along with dinuclear ruthenium 
species to generate a series of organometallic assemblies. Their photochemical properties are 
then investigated to see if the unique features of the azo moiety remain present in the 
ruthenium assemblies. 
 
3.2.2 Results and Discussion 
Four cationic ruthenium-azopyridine rectangles (32-35) were prepared, using different 
ruthenium starting materials (Scheme 11). The synthesis was realized in two steps. The first 
one involved reacting one equivalent of ruthenium dimer with two equivalents of silver 
triflate in dichloromethane at room temperature for 3 hours in order to form the triflate 
intermediate (not isolated). The second step involved filtering the reaction mixture (in order to 
eliminate the silver chloride formed during the first step) into a solution of one equivalent of 
4,4’-azopyridine in dichloromethane; this mixture was then refluxed for 10 hours. After 
isolation and purification, the tetracationic rectangles were obtained in good yields as their 
triflate salts. 
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Scheme 11: Synthesis and structures of ruthenium-azopyridine rectangles 32-35 
 
Simultaneously to this work, Stang and co-workers reported the synthesis and characterization 
of several ruthenium-azopyridine rectangles in order to investigate their anticancer properties, 
including 32, 34 and 35.[58] Therefore, the focus of the discussion will be on rectangle 33, as 
it was not reported before. All rectangles were characterized by 1H NMR spectroscopy, and 
for 33 by mass spectrometry, infrared spectroscopy, and UV-visible spectroscopy. The proton 
NMR spectra unsurprisingly show all signals slightly shifted compared to the starting 
materials. The infrared spectrum only shows bands corresponding to the C-H stretch of 
aromatics (~2900 cm-1) and the C=O stretch (~1600 cm-1) of the benzoquinone moiety. The 
nitrogen-nitrogen double bond can unfortunately not be seen in infrared spectroscopy due to 
its null dipolar moment and its symmetry. 33 was found to be poorly soluble in most organic 
solvents except for nitromethane – though soluble enough at concentrations required to 
perform UV-visible spectroscopy. 
In order to investigate the photochemical properties of these ruthenium-azopyridine 
assemblies, UV-visible absorption spectra were recorded to determine the optimal irradiation 
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wavelengths to use. Figure 21 presents the absorption spectra of azobenzene, azopyridine and 
metalla-rectangle 33. 
 
Figure 21: Normalized UV-visible absorption spectra of azobenzene, azopyridine and 33 in CH2Cl2 
 
A clear difference can be observed when comparing the spectra for azobenzene and 
azopyridine. While azobenzene has an absorption peak located at 319 nm, and is therefore 
suited for an irradiation with UV-A rays (315-400 nm), azopyridine has its absorption peak 
located at 283 nm, making it better suited for an irradiation using UV-C (100-280 nm) rays. 
Rectangle 33 presents a bathochromic shift of its UV absorption compared to azopyridine 
alone, in addition to a visible absorption peak which is due to a metal-ligand charge transfer. 
Since azopyridine has not been as extensively studied as azobenzene in the literature, 
irradiation experiments have been realized to investigate the isomerization of trans-
azopyridine to its cis form. A solution of azopyridine in dichloromethane (c = 1.0 x 10-5 
mol.L-1) was introduced into a closed quartz glass tube and submitted to irradiation with UV-
C rays; UV-visible spectra were recorded after certain amounts of time to monitor the 
isomerization process (Figure 22). 
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Figure 22: UV-spectra of azopyridine in CH2Cl2 before and after (10, 30 and 60 minutes, respectively) 
irradiation with UV-C rays 
 
The results are quite similar to what can be observed in the case of azobenzene.[59] Upon 
irradiation, the absorption peak located in the UV region decreases in intensity by 33%, while 
the visible absorption slightly increases. This suggests the successful isomerization of trans-
azopyridine to its cis form. No further changes of the spectrum were observed after more than 
one hour of irradiation. When left in the dark overnight, the solution presents a spectrum 
similar to the one prior to any irradiation, suggesting the successful reverted isomerization 
from cis- to trans-azopyridine. Since UV-visible spectroscopy does not allow for an easy 
quantification of the proportion of the two isomers, the same irradiation study was conducted, 
this time monitored by 1H NMR spectroscopy. Indeed, the proton signals of cis-azopyridine 
are shifted downfield compared to the trans form, making it easy to distinguish between the 
two isomers.[60] Their proportion can then be conveniently estimated by integration of the 
signals. The results of this study are presented in Figure 23. 
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Figure 23: 1H NMR spectra of trans-azopyridine in CD2Cl2 before (top) and after 30 minutes of irradiation with 
UV-C rays (bottom), with annotated cis-azopyridine peaks 
 
Only a partial conversion of trans-azopyridine to cis-azopyridine can be observed: integration 
of the signals reveals that a 13% conversion is attained after 30 minutes of irradiation. No 
further changes were observed even after a prolonged irradiation time. As observed with UV-
visible spectroscopy, disappearance of the peaks related to the cis isomer after leaving the 
solution in the dark overnight confirms the reverted isomerization. The reasons of this poor 
isomerization ratio compared to azobenzene are unclear; the first mention of this phenomenon 
was made by Kinugawa and co-workers, who came to the conclusion that the electron-
withdrawing nitrogen of the pyridyl group must have some kind of influence on the 
isomerization of the azo moiety.[61] Several years later, Espinet and co-workers reported 
values in concordance with the results described above, i.e. a similar decrease in absorbance 
(36%) and a 85/15 trans/cis ratio determined by proton NMR spectroscopy.[60] Bandara and 
Burdette later performed studies on several substituted azobenzenes,[59] including some 
t = 0 min 
t = 30 min 
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containing electron-withdrawing groups in their structure, but observed very similar behaviors 
to that of azobenzene, making azopyridine a particular case in that matter. 
Unfortunately, when rectangles 32-35 were submitted to irradiation with UV light (both UV-
A and UV-C rays irradiations were attempted), no changes were observed either by UV-
visible or NMR spectroscopy even after several days of irradiation. Several hypotheses can be 
formulated to explain this absence of isomerization. One is in the continuity of Kinugawa’s 
statement: if the low electron density of the aromatic rings has a negative influence on the 
isomerization properties, then the ruthenium-pyridyl bond further lowering this electronic 
density can enhance this influence, possibly leading to a very low or non-existent 
isomerization. In his work, Espinet synthesized gold (I) and silver (I) azopyridine complexes 
and indeed observed a diminution of the trans to cis conversion ratio compared to the free 
ligand, giving credit to this hypothesis. However, isomerization still occurred, even at low 
rates, implying there may be other reasons to the absence of isomerization in rectangles 32-35. 
Another hypothesis can be formed regarding the isomerization mechanism of azobenzenes. 
Several different mechanisms have been proposed for this transformation, mainly falling into 
two groups: rotation-based and inversion-based mechanisms (Scheme 12). 
 
Scheme 12: Rotation and inversion pathways for the isomerization mechanism of azobenzenes 
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The rotation mechanism involves a transition state where the two nitrogen atoms are linked by 
a single bond instead of a double bond, allowing free rotation along the N-N axis. The 
inversion mechanism involves a transition through a linear (180°) N=N-C angle between the 
trans and cis isomers. While there have been evidence of both types of mechanism, and while 
several pathways may happen simultaneously, each azobenzene system is unique and its 
isomerization mechanism depends on a number of factors, such as the structure of the 
molecule or the excited states involved in the isomerization process.[59] Regardless, some 
hypotheses can be proposed in the case of ruthenium-azopyridine rectangles 32-35. Indeed, it 
can be easily conceived that from a mechanical point of view, a rotation mechanism would 
not be feasible for a cyclic compound. In 32-35, each azopyridine is linked to the other one 
via the ruthenium clips, making impossible the complete rotation of the N-N bond to form the 
cis isomer. Since isomerization of cyclic azobenzene compounds have successfully been 
reported[62] – and logically deduced as inversion-driven – assumption can be made that 
rectangles 32-35, which show no trans to cis isomerization, need to operate through a rotation 
mechanism. The cyclic structure of these assemblies induces rigidity, thus preventing this 
mechanism to happen; a feature that Espinet’s complexes lack, possibly explaining why these 
more flexible compounds exhibit the isomerization of the azo moiety. 
 
3.2.3 Conclusion 
Four cationic ruthenium-azopyridine rectangles were successfully synthesized and 
characterized. Irradiation studies monitored by UV-visible and 1H NMR spectroscopies were 
performed to investigate their photochemical properties. Unfortunately, all rectangles failed to 
exhibit the trans to cis isomerization of the azo moiety. These results were interpreted by two 
hypotheses. The first one revolves around the poor isomerization activity of azopyridine itself, 
which could be worsened by the coordination of the pyridyl group to a metal. The second one 
revolves around the isomerization mechanism. The results obtained in this work point towards 
a rotation mechanism for these compounds, rendered impossible because of the cyclic nature 
of the assemblies. 
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3.3 Ruthenium-Anthracene Assemblies 
3.3.1 General 
Anthracene is a tricyclic aromatic molecule, consisting of three benzene rings arranged in a 
linear fashion. Anthracene is mostly obtained from coal tar, and is mainly used as the 
precursor of anthraquinone, which is used in the preparation of dyes such as the well-known 
red alizarin. Anthracene undergoes a photodimerization upon irradiation with UV light 
(Scheme 13).[63] The product of this [4+4] cycloaddition loses the aromaticity of the central 
rings, resulting in a curved structure, unlike the flat anthracene monomer. As consequences, 
the structural and spectral properties are greatly changed, and anthracene dimers tend to be 
insoluble in most common organic solvents.[64] The monomeric form can be retrieved upon 
heating or irradiation with a different wavelength (which depends on the absorption spectrum) 
of the dimer. 
 
Scheme 13: Photodimerization of anthracene 
 
Like many other aromatic molecules, anthracene is able to bind singlet oxygen through a 
[4+2] cycloaddition to form an endo-peroxide (Scheme 14).[65] These endo-peroxides can 
then be dissociated under certain conditions, releasing a singlet oxygen molecule while 
reverting to the anthracene starting compound. This feature has been the subject of much 
attention in the last years, as anthracene could in this case act as a vehicle to transport singlet 
oxygen; an interesting concept especially in medicinal chemistry, considering the high 
cytotoxicity of singlet oxygen.[66] 
Design and Synthesis of Light Responsive Arene Ruthenium Assemblies 
46 
 
 
Scheme 14: Formation of an endo-peroxide via the reaction of anthracene with singlet oxygen 
 
Anthracenes can be functionalized easily at multiple positions, making them interesting 
building blocks for the construction of supramolecular entities. Therefore, in this part of the 
work, anthracene is used as part of ruthenium metalla-assemblies; their synthesis, 
characterization, and the investigation of their photochemical properties will be discussed. 
 
3.3.2 Results and Discussion 
In order to make it a suitable ligand towards ruthenium, anthracene first needs to be 
functionalized. To achieve this purpose, 9,10-dibromoanthracene and 3-ethynylpyridine were 
submitted to a Sonogashira coupling reaction using a modified literature procedure to form 
ligand L36 (Scheme 15).[67] 
 
Scheme 15: Synthesis of anthracene-based ligand L36 
 
After purification, L36 was obtained as an orange solid with 28% yield, as 9-bromo-10-(3-
ethynylpyridine)anthracene, the mono-substituted product, is predominant even after a 
prolonged reaction time. L36 was only characterized by 1H and 13C NMR spectroscopy, as it 
was reported before, although not studied for its photodimerization properties.[68] This ligand 
was then used in the synthesis of metalla-rectangle 36, using the same procedure as previously 
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described (Scheme 16). The oxalato-bridged ruthenium dimer was chosen for its short Ru-Ru 
distance, in order to favor the [4+4] cycloaddition reaction of the anthracene moiety within 
the rectangle. 
 
Scheme 16: Synthesis of ruthenium-anthracene rectangle 36 
 
Rectangle 36 was obtained as a yellow solid with 83% yield, and was characterized by 1H and 
13C NMR spectroscopy, mass spectrometry, infrared spectroscopy, UV-visible spectroscopy 
and elemental analysis. Proton NMR signals present shifts compared to the starting materials, 
especially in the case of the pyridyl groups, more affected by the coordination to the 
ruthenium due to their proximity. Mass spectrometry confirms the formation of the structure 
pictured above with many characteristic peaks, such as [M-2OTf]2+, [M-3OTf]3+ and [M-
4OTf]4+. Infrared spectroscopy shows in particular the C=O stretch of the oxalato moiety 
(~1600 cm-1) and the C≡C (~2200 cm-1) stretch of the organic panels. Rectangle 36 is soluble 
in most organic solvents as well as in water, unlike hydrophobic ligand L36. 
Irradiation experiments were conducted both on ligand L36 and rectangle 36 in order to study 
the photodimerization process. First, a solution of L36 in CH2Cl2 (c = 1.0 x 10
-5 mol·L-1) was 
placed in a sealed quartz vessel and submitted to irradiation using UV-C rays; UV-visible 
spectra were recorded before and after irradiation, as shown in Figure 24. 
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Figure 24: UV-visible spectra of L36 in CH2Cl2 before and after 15 minutes of irradiation with UV-C rays 
 
The results obtained are very similar to previously reported studies on the photodimerization 
of anthracene species.[64] The monomeric form (L36) shows a strong absorption around 250 
nm due to the anthracene moiety and a visible absorption which is caused by the presence of 
the ethynylpyridine group. When irradiated, the UV-visible spectrum exhibits a disappearance 
of these absorptions, and a new absorption appears in the UV region, below 240 nm. It is 
worthy to mention that shorter irradiation times gave little to no changes, while irradiation 
times longer than 15 minutes did not induce any further change on the UV-visible spectrum. 
Upon irradiation, the pale yellow solution of L36 turned colorless, but no precipitation of the 
supposedly less soluble dimer was observed, certainly due to the low concentration of the 
medium. However, when a concentrated solution of L36 in CH2Cl2 was submitted to the same 
irradiation, white crystals appeared in the vessel. These crystals appeared to be quite poorly 
soluble in most solvents, but enough in CDCl3 so that a 
1H NMR spectrum could be recorded 
(Figure 25). 
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Figure 25: 1H NMR spectra of L36 in CDCl3 before (top) and after 60 minutes of irradiation with UV-C rays 
(bottom) 
 
Several downfield shifts can be observed after irradiation, especially regarding the signals 
corresponding to the pyridyl protons. Small additional peaks can also be observed on the 
spectrum, possibly due to a slight decomposition of the compound. Unfortunately, the 
concentration of the solution was not high enough to perform a well resolved 13C NMR 
spectrum. Nevertheless, all those information tend to confirm the formation of the dimeric 
form of L36. In this system, an undesired reaction can potentially occur: the intramolecular 
[2+2] cycloaddition of the parallel triple bonds is indeed a photochemically activated reaction. 
However, an infrared spectrum of the L36 dimer still presented the C≡C stretch band, and no 
band relative to a newly formed C=C bond – result of a potential [2+2] cycloaddition – was 
found. This result suggests that upon irradiation with UV-C light, the photodimerization of the 
anthracene moiety is favored compared to the cycloaddition of the triple bonds. 
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Unfortunately, no irradiation either with visible or UV light allowed to revert back to the 
monomeric form, possibly because of the lack of strong absorptions of the dimer. Since heat 
can be used to perform this transformation, thermolysis was attempted on the dimeric form of 
L36. No changes were observed when a diluted solution of the compound was heated gently 
(up to 100 °C, depending on the solvent), even after days (up to seven days). However, when 
the white crystals formed from the concentrated solution of L36 were heated up to the melting 
point (> 200 °C), an insoluble black slurry formed and could not be reverted to either the 
monomeric or dimeric form. This led to the conclusion that the dimerization of L36 was 
achieved but unfortunately irreversible. 
Nevertheless, the same irradiation studies were conducted on ruthenium-anthracene rectangle 
36. A solution of 36 in CH2Cl2 (c = 1.0 x 10
-5 mol·L-1) placed in a sealed quartz vessel was 
submitted to irradiation with UV-C rays; UV-visible spectra were recorded to monitor the 
changes (Figure 26). 
 
Figure 26: UV-visible spectra of 36 in CH2Cl2 before and after 30 minutes of irradiation with UV-C rays 
 
Similarly to L36, the UV-visible spectrum of 36 drastically changed upon 30 minutes of 
irradiation: all absorption bands disappeared and a new band formed in the UV region below 
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240 nm. This absorption profile suggests the successful dimerization of the anthracene moiety 
within the rectangle. However, as with L36, a return to the original state could not be 
achieved either by irradiation or heating. Irradiation of a more concentrated solution of 36 for 
the same amount of time did not induce any changes on the 1H NMR spectrum. After longer 
irradiation times (several hours), the solution progressively turned from yellow to black. 
Along with this change of aspect, the signals of the proton NMR spectrum became broader 
and the ratio of integrations changed, suggesting the breaking of the assembly and overall a 
possible decomposition of the compound. This could be explained by the fact that in more 
concentrated solutions, longer irradiation times are needed for the photodimerization to 
happen, but unfortunately also induce the breaking of the assembly. 
While rectangle 36 did not prove to be a fully functional photoswitchable assembly, 
interesting applications can still be found for ruthenium-anthracene entities. Like with many 
other ruthenium metalla-assemblies synthesized in our group, encapsulation of small aromatic 
molecules would certainly be possible in ruthenium-anthracene rectangles, although with 
ruthenium spacers longer than oxalato. Indeed, anthracene-type molecules make for excellent 
planar panels for the construction of such assemblies; moreover, their unique UV-visible 
properties – both absorption and emission – make them easy and convenient to identify. Such 
assemblies could also be used as vehicles for the transport of singlet oxygen via the formation 
of endo-peroxides, as mentioned in the introduction. This would be of high interest 
particularly in medicinal chemistry, as ionic assemblies such as 36 are generally water-soluble, 
whereas hydrophobic anthracene-based organic molecules are not. 
It is towards this perspective that collaborators at the University of Bordeaux, France, 
synthesized tetradentate ligand L37, which led to the synthesis of ruthenium metalla-assembly 
37 (Scheme 17). 
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Scheme 17: Synthesis of ruthenium-anthracene cage 37 
 
The synthesis was carried out following the standard procedure, i.e. reacting the anthracene 
ligand, the ruthenium clip – in this case, the naphtoquinonato-bridged dinuclear clip – and 
silver triflate. The resulting polycationic cage 37 was fully characterized by 1H and 13C NMR 
spectroscopy, using HSQC and HMBC 2D experiments in order to determine the position of 
the carbon signals; as well as by mass spectrometry, infrared spectroscopy, UV-visible 
spectroscopy and elemental analysis. The proton NMR shows a duplication of most signals 
compared to the starting materials due to the loss of symmetry in the three dimensional 
structure. The mass spectrum shows the typical [M-3OTf]3+ and [M-4OTf]4+ signals, 
confirming the formation of the assembly. The most characteristic signal in the infrared 
spectrum is the one corresponding to the C=O stretch of the naphtoquinone moiety (~1600 
cm-1). Despite its highly hydrophobic panels, 37 was found to be soluble in most solvents, 
including water. After purification and drying, 37 was sent to the University of Bordeaux in 
order to study the formation of the corresponding endo-peroxide, with the goal of obtaining a 
functional vehicle for the transport of singlet oxygen in aqueous medium. 
 
3.3.3 Conclusion 
In this work, anthracene-based ligand L36 and corresponding ruthenium rectangle 36 were 
successfully synthesized and characterized. Irradiation experiments were conducted for both 
compounds in order to study the photodimerization of the anthracene moiety. In the case of 
L36, it was found that the dimerization could occur but was unfortunately irreversible. In the 
case of 36, results suggested that the dimerization was possible for diluted solutions, but 
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prolonged irradiation of more concentrated solutions resulted in the breaking and 
decomposition of the assembly. This led to the search of alternative applications for 
ruthenium-anthracene species, such as the transport of singlet oxygen through the formation 
of endo-peroxides. In this regard, water-soluble ruthenium cage 37 was synthesized and sent 
to collaborators at the University of Bordeaux, France, in order to investigate this property for 
potential applications in medicinal chemistry. 
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3.4 Ruthenium-Dihydropyrene Assemblies 
3.4.1 General 
Pyrene is a tetracyclic aromatic molecule consisting of four benzene rings fused into each 
other. Like anthracene, pyrene is usually found in coal tar and is used in the preparation of 
dyes. Some of its derivatives are also used as molecular probes due to strong fluorescence 
emission properties. Dimethyldihydropyrene (DHP) is a pyrene derivative containing two 
methyl groups located at the center of the structure, pointing outside of the plane in opposite 
directions. In 1965, Boekelhe and co-workers reported that under irradiation with visible light, 
DHP undergoes a ring-opening reaction to give its metacyclophane tautomer (Scheme 
18).[69] This resulting cyclophanediene (CPD) is not flat like its pyrene counterpart, but 
rather possesses a stair-like structure. As expected, the spectral properties of the two isomers 
are largely different, resulting in an easy distinction between the two forms. 
 
Scheme 18: Photoisomerization of dimethyldihydropyrene 
 
The reverted cyclization reaction can be triggered by irradiation with UV light, or tends to 
occur thermally in the dark after a certain amount of time, the pyrene form being more stable. 
Many studies have been reported regarding the functionalization of dihydropyrenes and the 
influence of the substituents attached to their photochemical properties.[70] In most cases, 
dihydropyrene derivatives maintained the ability to photoisomerize. In the last part of this 
work, dihydropyrene is functionalized in order to become a suitable building block for the 
construction of ruthenium assemblies; their synthesis, characterization and properties will be 
discussed here. 
 
3.4.2 Results and Discussion 
Dihydropyrene precursor DHP was obtained through a multi-step synthesis described in 
Scheme 19, following procedures adapted from literature.[71] 
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Scheme 19: Synthesis of dihydropyrene precursor DHP 
 
This synthesis involved various chemical transformations and processes, of which the 
procedures are described in the Experimental Section. DHP was obtained successfully as a 
green powder with an overall yield of 42% (starting from 4-tert-butyltoluene) and its purity 
was confirmed by 1H NMR spectroscopy. It was then reacted with N-bromosuccinimide in 
order to give the dibrominated compound DHP-Br with a 66% yield after separation from the 
tetrabrominated side-product. DHP-Br could then be involved in a Suzuki cross-coupling 
reaction with 4-pyridineboronic acid in order to obtain ligand L38 (Scheme 20). 
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Scheme 20: Synthesis of DHP-Br and L38 
L38 was obtained as a green powder with a 53% yield and was characterized by 1H NMR 
spectroscopy, confirming the data previously reported in the literature.[72] Ligand L38 was 
then engaged in a reaction with naphtoquinonato-bridged ruthenium dinuclear clip and silver 
triflate in order to yield ruthenium-dihydropyrene rectangle 38 as a black powder with a 38% 
yield (Scheme 21). 
 
Scheme 21: Synthesis of ruthenium-dihydropyrene rectangle 38 
 
The structure of rectangle 38 was confirmed by 1H and 13C NMR spectroscopy, mass 
spectrometry, UV-visible spectroscopy and infrared spectroscopy. The most characteristic 
signals on the proton NMR spectrum are those corresponding to the naphtoquinone protons 
located at around 7 ppm, and those corresponding to the out of plane methyl groups on the 
pyrene moiety which are located at -4 ppm. The mass spectrum confirms the structure 
pictured above with the [M-2OTf]2+ and [M-3OTf]3+ characteristic peaks. The infrared 
spectrum unsurprisingly presents the C-H stretch of aromatics (~3000 cm-1) and the C=O 
stretch of the naphtoquinone moiety (~1600 cm-1). Rectangle 38 was found to be mildly 
soluble in most solvents, and unfortunately very poorly in water despite being a cationic 
species. 
Ligand L38 was extensively studied for its photochemical properties by Royal and co-
workers.[72] It was demonstrated that L38 could be fully converted to its open 
cyclophanediene (CPD) form via irradiation with visible light, and reverted to its closed form 
either via UV irradiation or heating. A few issues were reported though, such as the long 
irradiation time needed (more than 12 hours) to perform the DHP → CPD conversion, or the 
decomposition observed after long irradiation times with UV light for the backwards 
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transformation. In this work, irradiation experiments were conducted on L38 for reference 
and gave essentially the same results. 
UV-visible spectra were recorded both for ligand L38 and rectangle 38 in order to determine 
the optimal irradiation wavelength to perform the ring-opening reaction (Figure 27). 
 
Figure 27: Normalized UV-visible spectra of ligand L38 and rectangle 38 in CH2Cl2 
 
A few differences can be observed between the ligand and the ruthenium metalla-assembly. In 
the rectangle, a new absorption band in the UV region (240 nm) is present due to the arene-
ruthenium unit. Moreover, the two main bands corresponding to the dihydropyrene ligand 
(340 nm and 410 nm, respectively) are shifted in the rectangle compared to the free ligand: 
the former presents both a hypsochromic and a hypochromic effect, while the latter presents a 
bathochromic and a hyperchromic effect. These changes are however small enough that the 
same irradiation conditions as those used for L38 can be applied in the case of rectangle 38. 
Following these results, a solution of 38 in CH2Cl2 was submitted to irradiation with visible 
light for up to 30 hours. The changes were monitored by UV-visible spectroscopy and are 
presented in Figure 28. 
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Figure 28: UV-visible spectra of 38 in CH2Cl2 before and after (15 and 30 hours, respectively) irradiation with 
visible light 
 
After irradiation, a diminution of the intensity of the dihydropyrene-related bands can be 
observed, along with a rise of intensity of the shoulder band located at around 280 nm. 
Unsurprisingly, the band relative to the arene-ruthenium unit located at 240 nm does not 
exhibit any changes in intensity. These results are consistent to what was reported in the 
literature regarding the photochemistry of dihydropyrene compounds, and point towards the 
successful conversion of the dihydropyrene moiety to its cyclophanediene form within the 
assembly. Unfortunately, this photochemical reaction could not be monitored by NMR 
spectroscopy, as irradiation of a more concentrated solution of 38 did not yield any changes, 
even after seven days. However, it is noteworthy to mention that no signs of decomposition 
were observed either in the UV-visible or proton NMR spectra, even after such prolonged 
irradiation times. 
The open form of rectangle 38 (noted o-38) was then submitted to irradiation with UV-C light 
in order to trigger the reverted CPD → DHP reaction. The changes were once again 
monitored by UV-visible spectroscopy; the results of this study are presented in Figure 29. 
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Figure 29: Normalized UV-visible spectra of 38, o-38 and o-38 after 15 minutes of irradiation with UV-C rays 
 
Changes occurred on the UV-visible spectrum after only 15 minutes of irradiation. 
Unfortunately, the resulting spectrum did not correspond to that of the closed form of the 
rectangle (38), as can be seen in the figure. Instead, the resulting spectrum presents a 
disappearance of the visible bands and a further raise of the intensity of the UV band located 
at around 280 nm. No further changes were observed when irradiated with UV-C light for a 
longer time, and the same results were obtained when the solution of o-38 was submitted to 
irradiation with UV-A light or heating. This information, in addition to previous reports on 
L38,[72] tend to the conclusion that a decomposition of the product occurred. Moreover, 
changes happened in a very short time compared to what was needed in order to perform the 
ring-opening reaction, suggesting a drastic transformation different from a slow 
photochemical process. This hypothesis was further supported by the disappearance of the 
characteristic peaks of the metalla-assembly when the UV-irradiated solution of o-38 was 
submitted to mass spectrometry. These results, in correlation with those obtained in the case 
of anthracene assemblies, also suggest that ruthenium metalla-assemblies could be subject to 
decomposition when exposed to strong UV irradiations. 
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3.4.3 Conclusion 
In this work, a multi-step organic synthesis was conducted in order to obtain dihydropyrene 
ligand L38 which was used to synthesize ruthenium metalla-assembly 38. While the 
reversible DHP ↔ CPD photochemical transformation could not be fully achieved, 
ruthenium-dihydropyrene rectangle 38 proved to be a semi-functional photoswitchable 
assembly. The opening of the dihydropyrene moiety was indeed possible within the assembly, 
even if only at low concentrations. This feature, along with an optimization of the structure of 
ruthenium-dihydropyrene species, could potentially be used in order to release a guest 
molecule from inside the cavity of the assembly. Such compounds could also be used for the 
transport of singlet oxygen, as dihydropyrene shares this property with anthracene.[73] 
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Chapter 4: General Conclusion and Perspectives 
 
The work presented in this thesis involved the design and synthesis of novel arene ruthenium 
species, and was divided in two sections. In the first one (Chapter 2), the synthesis of 
hydrazinyl-thiazole ruthenium complexes was conducted in order to test their biological 
properties against human cancerous cell lines. The strategy of this project was to combine the 
activity of the hydrazinyl-thiazole moiety – along with other organic pharmacophore groups – 
and that of the arene ruthenium unit. This project spawned three series of complexes, as 
shown in Figure 30. 
 
Figure 30: General structures of the three series of hydrazinyl-thiazole ruthenium complexes synthesized 
 
The first series of complexes, composed of phenyl derivatives, was tested on cancerous and 
healthy cell lines and gave very satisfying results. These initial results led to an optimization 
of the structure of the complexes, as well as the synthesis of compounds bearing different 
aromatic moieties, namely phenothiazine (2nd series) and indole (3rd series). All complexes 
presented many interesting features, such as unique spectroscopic signatures and a good 
solubility in water, ideal for biological applications. 
These hydrazinyl-thiazole ruthenium complexes are the first of their kind, and represent the 
birth of a new family of promising anticancer compounds. The strategy of combining 
biologically active organic and organometallic groups proved to be efficient, and many more 
derivatives could be explored in order to further deepen this project. Indeed, the number of 
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organic anticancer compounds is quite large, and functionalization of hydrazinyl-thiazole 
molecules was found to be relatively easy. Following these examples, other pharmacophore 
moieties could be included as part of the ligands in order to make the corresponding 
complexes. Phenyl derivatives containing alkylating groups could for instance be synthesized, 
in order to obtain structures resembling that of aromatic mustards. Other heterocyclic 
compounds such as benzofuran compounds are also known to exhibit anticancer 
properties[74] and could therefore be included in the structure of hydrazinyl-thiazole ligands, 
as pictured in Figure 31. 
 
Figure 31: General structures of potential future hydrazinyl-thiazole arene ruthenium complexes, based on 
aromatic mustards (left) and benzofuran (right) 
 
A large number of compounds could be synthesized this way, and optimization of the 
structures could be achieved thanks to the results obtained with the first three series. This 
would help to further expand this family of complexes, and provide advances in the search of 
highly active organometallic anticancer compounds. 
In the second part of this work (Chapter 3), organic molecules containing a photoswitchable 
moiety were used in the synthesis of ruthenium metalla-assemblies. The aim of this project 
was to obtain structures that could be light-triggered in order to switch between two different 
states, thus potentially providing a novel means to control the encapsulation and release of 
guest molecules. Three classes of molecules were used, namely azobenzene, anthracene, and 
dihydropyrene derivatives (Figure 32). 
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Figure 32: General structures of the three classes of photoswitchable molecules presented in Chapter 3 
 
Each of those molecules was functionalized in order to become suitable ligands and used in 
the synthesis of metalla-rectangles, using various dinuclear ruthenium spacers. In the case of 
azobenzene derivatives, the trans-cis isomerization of the azo moiety could not occur in the 
assembly, its rigidity making the rotation around the N=N bond impossible. While the 
synthesized assemblies were not photoswitchable, the results gave insight on the 
isomerization mechanism of such compounds. In the case of both anthracene and 
dihydropyrene ruthenium assemblies, semi-functional photoswitchable rectangles were 
obtained. Indeed, the light-triggered reactions (dimerization of anthracene, ring-opening 
reaction of dihydropyrene) could be performed at low concentrations but unfortunately could 
not be reverted. Nevertheless, these assemblies hold a particular interest thanks to many 
relevant properties, such as their potential ability to transport singlet oxygen in aqueous media. 
The synthesis and study of these compounds hopefully represents the beginning of a new field 
of ruthenium organometallic chemistry. Indeed, many strategies are yet to be explored in 
order to achieve the goal of obtaining fully functional ruthenium photoswitchable assemblies. 
In this project, the photoactive molecules have been included as the panels of the assemblies. 
An alternative to this strategy would be to include them as part of the ruthenium-ruthenium 
spacers. Indeed, 2,5-dihydroxy-1,4-benzoquinone, which has been used as a ruthenium-
ruthenium spacer in our group for many years, can be functionalized via a series of 
General Conclusion and Perspectives 
64 
 
reactions.[75] This feature could be exploited in order to include a photoswitchable moiety 
such as anthracene on the ruthenium clip (Scheme 22). 
 
Scheme 22: Potential structure of a ruthenium assembly bearing a benzoquinone spacer functionalized with 
anthracene, and formation of the corresponding endo-peroxide 
 
In this example, the size and shape of the assembly could be tuned either by changing the 
panel or by changing the way anthracene is connected to the benzoquinone group. This would 
allow to determine the optimal structure for the photodimeriazion of anthracene to block the 
cavity of the assembly, thus leading to an open-closed photoswitchable system. This kind of 
assembly could also be used for the transport of singlet oxygen, the flexibility around the 
anthracene moiety potentially facilitating the formation of the endo-peroxides. 
Other classes of photoswitchable molecules could also be used as part of ruthenium metalla-
assemblies. Among them, hemithioindigos (Scheme 23) could be promising candidates for 
this prospect. These molecules have indeed proven to be efficient bistable photoswitches; 
moreover, their asymmetrical nature makes them easy to functionalize, leading to a 
convenient tunability of their structure.[76] This would allow the creation of a whole new 
family of compounds, with potentially interesting photochemical properties. 
 
Scheme 22: Photochemical isomerization of hemithioindigos 
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In conclusion, this thesis represents advances in the design and synthesis of new arene 
ruthenium species. It confirmed the benefit of combining a ruthenium core with organic 
pharmacophores in order to create a family of highly cytotoxic compounds. This class of 
molecules could in the future be further improved and diversified, with the goal of achieving 
better activity and selectivity. This thesis also explored a new field of ruthenium 
supramolecular chemistry, with the synthesis of several assemblies bearing photoswitchable 
moieties. Even though the primary goal of this project – the synthesis of fully functional 
photoswitchable ruthenium assemblies – was not completely attained, the results provided 
very useful information on the photochemistry of ruthenium metalla-assemblies. This 
represents the ground work of a project that could hopefully be deepened by the optimization 
of the designed structures, in order to achieve the synthesis of light-triggered ruthenium 
assemblies. 
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Chapter 5: Experimental Section 
 
5.1 General 
Solvents of analytical grade purchased from Acros Organics, Honeywell or VWR 
International S.A.S were used for syntheses and not degassed or distilled prior to use, unless 
stated otherwise. All organic starting materials were purchased from Acros Organics, Sigma-
Aldrich, Fluka, Alfa Aesar or TCI Europe and used as received. The silica gel used for 
column chromatography (32-64, 60 Å) was purchased from Brunschwig. The starting material 
[(η6-p-MeC6H4Pri)Ru(μ2-Cl)Cl]2 was prepared according to published methods.[16] The 
ruthenium dinuclear spacers dhbq,[19] dcbq,[18] oxa[77] and dhnq[78] used in this work 
were synthesized according to published methods. The hydrazinyl-thiazole derivatives (L1-
L31) were also prepared according to the literature.[31] All other reagents were bought from 
commercial sources and were used without further purification. 
The 1H and 13C NMR spectra were recorded on a Bruker Avance II 400 spectrometer, using 
the residual protonated solvent as an internal standard. Infrared spectra were recorded as KBr 
pellets on a PerkinElmer FTIR Spectrum One spectrometer. Elemental analyses were 
performed by the Mikroelementarisches Laboratorium, ETH Zürich (Zürich, Switzerland). 
Electrospray ionization mass spectra were recorded in positive-ion mode with a Bruker FTMS 
4.7T BioAPEX II mass spectrometer (University of Fribourg, Switzerland). Microwave 
assisted syntheses were performed in sealed vessels using a CEM Discover LabMate 
instrument, ensured with online inside temperature and pressure controls. UV-visible spectra 
were recorded on a PerkinElmer Lambda 25 spectrophotometer. Fluorescence spectra were 
recorded on a PerkinElmer LS 50 B luminescence spectrophotometer. Irradiation studies were 
performed using a Luzchem LZC-ORG photoreactor equipped with corresponding lamps. 
A crystal of complex 12 was mountd on a Stoe Image Plate Diffraction system equipped with 
a Φ circle goniometer, using Mo Kα graphite monochromated radiation (λ = 0.71073 Å) with 
Φ range 0-200°. The structure was solved by direct methods using the program SHELXS-97, 
while the refinement and all further calculations were carried out using SHELXL-97.[79] 
Figure 14 was drawn with ORTEP [80] and the structural data deposited at The Cambridge 
Crystallographic Data Centre: CCDC 1063589. These data can be obtained free of charge 
from The Cambridge Crystallographic Data Centre. 
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The human cervical cancer cells (HeLa), the human ovarian cancer cells (A2780), the 
cisplatin-resistant human ovarian cancer cells (A2780cisR) and the noncancerous cells (HFL-
1) were obtained from the European Center of Cell Cultures (ECACC). These cell lines were 
cultivated under sterile conditions by using RPMI 1640 (Sigma-Aldrich) growth media. This 
medium was supplemented with fetal calf serum (FCS, Sigma-Aldrich, 5%), antibiotics 
(penicillin-streptomycin, Actavis Sindan Pharma, 0.1%), and glutamine (Sigma-Aldrich, 
0.1%) at 37 °C and CO2 (5%). 
The cytotoxicity activity was determined using the MTT assay. The cells were seeded in 96-
well plates with 100 μL of cell solution (cca. 10.000 cells/well) and incubated for 24 hours. 
Compounds 1-16 were initially dissolved in DMSO, followed by a series of successive 
dilutions using RPMI 1640 media, so that the final concentration of DMSO was under 0.1%. 
The cells were treated with complexes 1-16 (concentrations between 0.1 μM and 100 μM) for 
24 hours, with a final volume in the well of 200 μL. After the treatment, the culture media 
were removed, MTT-Hanks media solution was added to each well, and the plates were 
incubated for a further two hours. The formazan crystals formed by the mitochondrial 
dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, quantified 
by colorimetric measurements, is directly proportional to the amount of formazan crystals 
formed in the cells, and is an indicator of the cellular viability. The plates were measured with 
a multimode microplate reader (Biotek Synergy 2 Multi-Mode Microplate Reader with SQ 
Xenon Flash light source), and absorbance was detected at 570 nm. Cisplatin and oxaliplatin 
drugs were used as a positive control in the experiments, in the same concentrations as the 
studied compounds. All of the experiments were performed in triplicate. Values are given as 
the mean ± SEM. Data are represented as averages of independent experiments, performed in 
triplicate. The experimental data were processed with Graph Pad Prism 5 biostatistics 
software. 
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5.2 Syntheses and Characterizations 
5.2.1 Hydrazinyl-Thiazole Ruthenium Complexes 
General procedures for the synthesis of complexes 1-31: 
General procedure A: A mixture of [(η6-p-MeC6H4Pri)Ru(μ2-Cl)Cl]2 (1 equivalent) and 
hydrazinyl-thiazole (2 equivalents) in methanol was stirred at room temperature for 10 hours. 
The solvent was then completely removed under vacuum, and the residue was dissolved in 
dichloromethane. The product was precipitated by pouring this solution into n-pentane, 
filtering, washing multiple times with n-pentane, and finally drying under vacuum to afford 
the corresponding salts in good yields. 
General procedure B: A reaction mixture containing [(η6-p-MeC6H4Pri)Ru(μ2-Cl)Cl]2 (1 
equivalent) and the hydrazinyl-thiazole (2 equivalents) in dichloromethane was introduced 
into a quartz reaction vessel, which was sealed and then subjected to microwave irradiation 
for 30 minutes at an internal temperature of 60°C. The mixture was then concentrated under 
vacuum, and the residue was precipitated with n-pentane, filtered, and washed multiple times 
with n-pentane, and the solid was dried under vacuum. 
1: [(η6-p-MeC6H4Pri)Ru(L1)Cl]Cl. Yield: 67%. 1H NMR (CDCl3, 400 MHz): δ = 1.07 (d, 
3JH−H = 7.1 Hz, 3H), 1.15 (d, 
3JH−H = 7.1 Hz, 3H), 2.26 (s, 3H), 2.46 (s, 3H), 2.57 (sept, 
3JH−H 
= 7.1 Hz, 1H), 4.52 (d, 3JH−H = 6.0 Hz, 1H), 5.06 (d, 
3JH−H = 6.0 Hz, 1H), 5.18 (d, 
3JH−H = 6.0 
Hz, 1H), 5.44 (d, 3JH−H = 6.0 Hz, 1H), 6.49 (s, 1H), 7,55−7.57 (m, 3H), 8.12 (m, 2H), 9.32 (s, 
1H), 15.63 (s, 1H) ppm. ESI-MS m/z (+): 488.1 [M-Cl]+. Anal. Calcd for C21H25N3SCl2Ru: C, 
48.18; H, 4.81; N, 8.03. Found: C, 48.18; H, 4.83; N, 7.96. IR (KBr): 2958 (m), 2919 (m), 
2525 (s), 1557 (s), 1505 (s), 1387 (m), 1306 (s), 1257 (m), 1093 (m) cm−1. 
2: [(η6-p-MeC6H4Pri)Ru(L2)Cl]Cl. Yield: 62%. 1H NMR (CDCl3, 400 MHz): δ = 0.96 (d, 
3JH−H = 6.8 Hz, 3H), 1.01 (d, 
3JH−H = 6.8 Hz, 3H), 2.14 (s, 3H), 2.36 (sept, 
3JH−H = 6.8 Hz, 1H), 
4.03 (d, 3JH−H = 5.4 Hz, 1H), 4.25 (d, 
3JH−H = 5.4 Hz, 1H), 4.65−4.66 (m, 2H), 6.74 (s, 1H), 
7.54− 7.56 (m, 6H), 7.90−7.91 (m, 2H), 8.12−8.13 (m, 2H), 9.30 (s, 1H), 15.88 (s, 1H) ppm. 
ESI-MS m/z (+): 550.1 [M-Cl]+. Anal. Calcd for C26H27N3SCl2Ru·0.5 H2O: C, 52.52; H, 4.75; 
N, 7.07. Found: C, 52.63; H, 4.55; N, 6.90. IR (KBr): 2916 (m), 2501 (m), 1575 (s), 1500 (s), 
1384 (m), 1313 (m), 1090 (s) cm−1. 
3: [(η6-p-MeC6H4Pri)Ru(L3)Cl]Cl. Yield: 61%. 1H NMR (CDCl3, 400 MHz): δ = 1.08 (d, 
3JH−H = 6.9 Hz, 3H), 1.16 (d, 
3JH−H = 6.9 Hz, 3H), 2.28 (s, 3H), 2.45 (s, 3H), 2.56 (sept, 
3JH−H 
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= 6.9 Hz, 1H), 2.82 (s, 3H), 4.51 (d, 3JH−H = 5.8 Hz, 1H), 5.09 (d, 
3JH−H = 5.8 Hz, 1H), 5.22 (d, 
3JH−H = 5.8 Hz, 1H), 5.41 (d, 
3JH−H = 5.8 Hz, 1H), 7.58−7.60 (m, 3H), 8.14 (d, 3JH−H = 7.1 Hz, 
2H), 9.34 (s, 1H), 12.95 (s, 1H) ppm. ESI-MS m/z (+): 529.9 [M-Cl]+. Anal. Calcd for 
C23H27N3OSCl2Ru: C, 48.85; H, 4.81; N, 7.43. Found: C, 48.96; H, 5.34; N, 6.87. IR (KBr): 
2965 (w), 1637 (m), 1568 (s), 1475 (s), 1374 (m), 1309 (s) cm−1. 
4: [(η6-p-MeC6H4Pri)Ru(L4)Cl]Cl. Yield: 71%. 1H NMR (CDCl3, 400 MHz): δ = 1.08 (d, 
3JH−H = 6.8 Hz, 3H), 1.16 (d, 
3JH−H = 6.8 Hz, 3H), 1.35 (t, 
3JH−H = 7.2 Hz, 3H), 2.20 (s, 3H), 
2.60 (sept, 3JH−H = 6.8 Hz, 1H), 3.80 (s, 2H), 4.29 (q, 
3JH−H = 7.2 Hz, 2H), 4.37 (d, 
3JH−H = 5.9 
Hz, 1H), 5.19 (d, 3JH−H = 5.9 Hz, 1H), 5.24 (d, 
3JH−H = 5.9 Hz, 1H), 5.62 (d, 
3JH−H = 5.9 Hz, 
1H), 6.83 (s, 1H), 7.47 (dd, 3JH−H = 8.4 Hz, 
4JH−H = 1.9 Hz, 1H), 7.58 (d, 
4JH−H = 1.9 Hz, 1H), 
8.42 (d, 3JH−H = 8.4 Hz, 1H), 9.24 (s, 1H), 16.08 (s, 1H) ppm. ESI-MS m/z (+): 630.0 [M-Cl]
+. 
Anal. Calcd for C24H27N3O2SCl4Ru·H2O: C, 42.24; H, 4.28; N, 6.16. Found: C, 42.43; H, 
4.08; N, 6.31. IR (KBr): 2918 (m), 1732 (m), 1589 (s), 1551 (s), 1470 (s), 1384 (s), 1259 (m), 
1146 (m), 1083 (m), 1056 (m) cm−1. 
5: [(η6-p-MeC6H4Pri)Ru(L5)Cl]Cl. Yield: 51%. 1H NMR (CDCl3, 400 MHz): δ = 1.07 (d, 
3JH−H = 7.1 Hz, 3H), 1.13 (d, 
3JH−H = 7.1 Hz, 3H), 2.49 (s, 3H), 2.54 (sept, 
3JH−H = 7.1 Hz, 1H), 
2.63 (s, 3H), 2.79 (s, 3H), 5.08 (d, 3JH−H = 5.4 Hz, 1H), 5.35 (d, 
3JH−H = 5.4 Hz, 1H), 5.57 (d, 
3JH−H = 5.4 Hz, 1H), 5.65 (d, 
3JH−H = 5.4 Hz, 1H), 7.31 (d, 
3JH−H = 8.6 Hz, 1H), 7.42 (s, 1H), 
7.98 (d, 3JH−H = 8.6 Hz, 1H), 8.29 (s, 1H), 12.83 (s, 1H) ppm. ESI-MS m/z (+): 599.8 [M-Cl]
+. 
Anal. Calcd for C23H25N3OSCl4Ru·H2O: C, 42.34; H, 4.17; N, 6.44. Found: C, 42.66; H, 3.96; 
N, 6.30. IR (KBr): 2975 (m), 1604 (m), 1564 (m), 1384 (s), 1328 (s), 1055 (s) cm−1. 
6: [(η6-p-MeC6H4Pri)Ru(L6)Cl]Cl. Yield: 68%. 1H NMR (CDCl3, 400 MHz): δ = 1.07 (d, 
3JH−H = 6.2 Hz, 3H), 1.15 (d, 
3JH−H = 6.2 Hz, 3H), 1.33 (t, 
3JH−H = 6.6 Hz, 3H), 2.21 (s, 3H), 
2.62 (sept, 3JH−H = 6.2 Hz, 1H), 2.78 (s, 3H), 4.27 (q, 
3JH−H = 6.6 Hz, 2H), 5.12 (d, 
3JH−H = 5.5 
Hz, 1H), 5.18 (d, 3JH−H = 5.5 Hz, 1H), 5.41 (d, 
3JH−H = 5.5 Hz, 1H), 5.59 (d, 
3JH−H = 5.5 Hz, 
1H), 7.44 (d, 3JH−H = 8.2 Hz, 1H), 7.56 (s, 1H), 8.55 (d, 
3JH−H = 8.2 Hz, 1H), 8.78 (s, 1H), 
13.43 (s, 1H) ppm. ESIMS m/z (+): 630.0 [M-Cl]+. Anal. Calcd for C24H27N3O2SCl4Ru: C, 
43.39; H, 4.10; N, 6.32. Found: C, 43.47; H, 4.24; N, 6.26. IR (KBr): 2965 (w), 1709 (m), 
1585 (s), 1474 (s), 1373 (s), 1317 (s), 1276 (s), 1099 (s) cm−1. 
7: [(η6-p-MeC6H4Pri)Ru(L7)Cl]Cl. Yield: 78%. 1H NMR (CDCl3, 400 MHz): δ = 1.07 (d, 
3JH−H = 6.9 Hz, 3H), 1.14 (d, 
3JH−H = 6.9 Hz, 3H), 2.27 (s, 3H), 2.46 (s, 3H), 2.54 (sept, 
3JH−H 
= 6.9 Hz, 1H), 4.81 (d, 3JH−H = 5.7 Hz, 1H), 5.09 (d, 
3JH−H = 5.7 Hz, 1H), 5.18 (d, 
3JH−H = 5.7 
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Hz, 1H), 5.44 (d, 3JH−H = 5.7 Hz, 1H), 6.48 (s, 1H), 7.12 (d, 
3JH−H = 8.4 Hz, 2H), 7.70 (d, 
3JH−H 
= 8.4 Hz, 2H), 8.76 (s, 1H), 14.23 (s, 1H) ppm. ESI-MS m/z (+): 504.1 [M-Cl]+. Anal. Calcd 
for C21H25N3OSCl2Ru·0.5 H2O: C, 45.99; H, 4.78; N, 7.66. Found: C, 45.90; H, 4.98; N, 7.12. 
IR (KBr): 2965 (m), 1607 (s), 1552 (m), 1509 (s), 1383 (m), 1284 (m), 1254 (m), 1174 (m) 
cm−1. 
8: [(η6-p-MeC6H4Pri)Ru(L8)Cl]Cl. Yield: 69%. 1H NMR (CDCl3, 400 MHz): δ = 0.96 (d, 
3JH−H = 6.3 Hz, 3H), 1.01 (d, 
3JH−H = 6.3 Hz, 3H), 2.16 (s, 3H), 2.32 (sept, 
3JH−H = 6.3 Hz, 1H), 
3.95 (d, 3JH−H = 5.7 Hz, 1H), 4.60 (d, 
3JH−H = 5.7 Hz, 1H), 4.71−4.73 (m, 2H), 6.73 (s, 1H), 
7.15− 7.18 (m, 2H), 7.54−7.55 (m, 3H), 7.75−7.77 (m, 2H), 7.90−7.92 (m, 2H), 8.77 (s, 1H), 
14.25 (s, 1H) ppm. ESI-MS m/z (+): 565.9 [M-Cl]+. Anal. Calcd for C26H27N3OSCl2Ru·H2O: 
C, 50.40; H, 4.72; N, 6.78. Found: C, 50.17; H, 4.61; N, 6.32. IR (KBr): 2969 (s), 1605 (s), 
1572 (s), 1508 (s), 1278 (m), 1174 (m) cm−1. 
9: [(η6-p-MeC6H4Pri)Ru(L9)Cl]Cl. Yield: 73%. 1H NMR (CDCl3, 400 MHz): δ = 1.13 (d, 
3JH−H = 6.8 Hz, 3H), 1.20 (d, 
3JH−H = 6.8 Hz, 3H), 2.33 (s, 3H), 2.50 (s, 3H), 2.63 (sept, 
3JH−H 
= 6.8 Hz, 1H), 3.96 (s, 3H), 4.83 (d, 3JH−H = 5.8 Hz, 1H), 5.15 (d, 
3JH−H = 5.8 Hz, 1H), 5.26 (d, 
3JH−H = 5.8 Hz, 1H), 5.50 (d, 
3JH−H = 5.8 Hz, 1H), 6.51 (s, 1H), 7.10 (d, 
3JH−H = 8.8 Hz, 2H), 
8.18 (d, 3JH−H = 8.8 Hz, 2H), 9.25 (s, 1H), 15.36 (s, 1H) ppm. ESI-MS m/z (+): 517.9 [M-Cl]
+. 
Anal. Calcd for C22H27N3OSCl2Ru: C, 47.74; H, 4.92; N, 7.59. Found: C, 47.52; H, 4.94; N, 
7.40. IR (KBr): 2966 (w), 2481 (w), 1604 (s), 1554 (m), 1509 (s), 1378 (w), 1306 (m), 1266 
(s), 1180 (m), 1087 (w) cm−1. 
10: [(η6-p-MeC6H4Pri)Ru(L10)Cl]Cl. Yield: 75%. 1H NMR (CDCl3, 400 MHz): δ = 0.98 (d, 
3JH−H = 6.8 Hz, 3H), 1.02 (d, 
3JH−H = 6.8 Hz, 3H), 2.17 (s, 3H), 2.38 (sept, 
3JH−H = 6.8 Hz, 1H), 
4.00 (d, 3JH−H = 6.1 Hz, 1H), 4.53 (d, 
3JH−H = 6.1 Hz, 1H), 4.70 (d, 
3JH−H = 6.1 Hz, 1H), 4.74 
(d, 3JH−H = 6.1 Hz, 1H), 6.72 (s, 1H), 7.06 (d, 
3JH−H = 8.7 Hz, 2H), 7.55 (m, 3H), 7.91 (m, 2H), 
8.15 (d, 3JH−H = 8.7 Hz, 2H), 9.20 (s, 1H), 15.67 (s, 1H) ppm. ESI-MS m/z (+): 580.1 [M-Cl]
+. 
Anal. Calcd for C27H29N3OSCl2Ru·H2O: C, 51.18; H, 4.93; N, 6.63. Found: C, 51.36; H, 4.78; 
N, 6.49. IR (KBr): 2966 (w), 1604 (s), 1574 (m), 1509 (s), 1309 (m), 1271 (s), 1178 (m), 1085 
(m) cm−1. 
11: [(η6-p-MeC6H4Pri)Ru(L11)Cl]Cl. Yield: 72%. 1H NMR (CDCl3, 400 MHz): δ = 1.10 (d, 
3JH−H = 6.9 Hz, 3H), 1.16 (d, 
3JH−H = 6.9 Hz, 3H), 1.33 (t, 
3JH−H = 7.1 Hz, 3H), 2.32 (s, 3H), 
2.57 (sept, 3JH−H = 6.9 Hz, 1H), 2.82 (s, 3H), 3.93 (s, 3H), 4.30 (q, 
3JH−H = 7.1 Hz, 2H), 4.78 
(d, 3JH−H = 5.9 Hz, 1H), 5.13 (d, 
3JH−H = 5.9 Hz, 1H), 5.26 (d, 
3JH−H = 5.9 Hz, 1H), 5.45 (d, 
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3JH−H = 5.9 Hz, 1H), 7.07 (d, 
3JH−H = 8.7 Hz, 2H), 8.15 (d, 
3JH−H = 8.7 Hz, 2H), 9.20 (s, 1H), 
16.01 (s, 1H) ppm. ESI-MS m/z (+): 589.9 [M-Cl]+. Anal. Calcd for 
C25H31N3O3SCl2Ru·CH2Cl2: C, 43.95; H, 4.68; Found: C, 43.67; H, 4.75. IR (KBr): 2966 (w), 
1710 (m), 1604 (s), 1575 (s), 1509 (s), 1477 (m), 1372 (m), 1314 (s), 1268 (s), 1178 (m), 
1099 (s) cm−1. 
12: [(η6-p-MeC6H4Pri)Ru(L12)Cl]Cl. Yield: 70%. 1H NMR (CDCl3, 400 MHz): δ = 1.13 (d, 
3JH−H = 6.4 Hz, 3H), 1.20 (d, 
3JH−H = 6.4 Hz, 3H), 2.35 (s, 3H), 2.47 (s, 3H), 2.62 (sept, 
3JH−H 
= 6.4 Hz, 1H), 2.86 (s, 3H), 3.96 (s, 3H), 4.81 (d, 3JH−H = 4.8 Hz, 1H), 5.16 (d, 
3JH−H = 4.8 Hz, 
1H), 5.29 (d, 3JH−H = 4.8 Hz, 1H), 5.46 (d, 
3JH−H = 4.8 Hz, 1H), 7.10 (d, 
3JH−H = 8.0 Hz, 2H), 
8.20 (d, 3JH−H = 8.0 Hz, 2H), 9.18 (s, 1H), 12.46 (s, 1H) ppm. ESI-MS m/z (+): 560.1 [M-Cl]
+. 
Anal. Calcd for C24H29N3O2SCl2Ru·H2O: C, 46.98; H, 5.09; N, 6.85. Found: C, 46.94; H, 
4.91; N, 6.77. IR (KBr): 2963 (w), 1638 (m), 1604 (s), 1574 (m), 1510 (s), 1475 (m), 1374 
(m), 1307 (s), 1262 (s), 1179 (m) cm−1. Crystal data: Monoclinic space group P21/c (No. 14), 
cell parameters a = 16.2513(19), b = 15.1904(12), and c = 13.3986(13) Å, β = 107.817(8), V = 
3149.0(5) Å3, T = 173(2) K, Z = 4, Dc = 1.256 g cm
−3, F(000) 1216, λ (Mo Kα) = 0.71073 Å, 
8557 reflections measured, and 2494 unique (Rint = 0.2499), which were used in all 
calculations. The non-hydrogen atoms were refined anisotropically, using weighted full-
matrix least-squares on F2 with 304 parameters. R1 = 0.0515 (I > 2σ(I)) and wR2 = 0.0975, 
GOF = 0.629; max/min residual density 0.447/−0.729 eÅ−3. 
13: [(η6-p-MeC6H4Pri)Ru(L13)Cl]Cl. Yield: 70%. 1H NMR (CDCl3, 400 MHz): δ = 1.06 (d, 
3JH−H = 6.8 Hz, 3H), 1.15 (d, 
3JH−H = 6.8 Hz, 3H), 2.30 (s, 3H), 2.45 (s, 3H), 2.59 (sept, 
3JH−H 
= 6.8 Hz, 1H), 4.63 (d, 3JH−H = 5.6 Hz, 1H), 5.11 (d, 
3JH−H = 5.6 Hz, 1H), 5.17 (d, 
3JH−H = 5.6 
Hz, 1H), 5.46 (d, 3JH−H = 5.6 Hz, 1H), 6.44 (s, 1H), 7.51 (m, 2H), 7.91 (d, 
3JH−H = 7.1 Hz, 1H), 
9.24 (s, 1H), 13.95 (s, 1H) ppm. ESI-MS m/z (+): 524.1 [M-Cl]+. Anal. Calcd for 
C21H24N3SCl3Ru·CH2Cl2: C, 41.10; H, 4.08; N, 6.54; Found: C, 41.40; H, 4.08; N, 6.33. IR 
(KBr): 2966 (w), 1604 (s), 1509 (s), 1375 (m), 1309 (s), 1261 (m), 1178 (m) cm−1. 
14: [(η6-p-MeC6H4Pri)Ru(L15)Cl]Cl. Yield: 61%. 1H NMR (CDCl3, 400 MHz): δ = 1.11 (d, 
3JH−H = 6.8 Hz, 3H), 1.28 (d, 
3JH−H = 6.8 Hz, 3H), 2.16 (s, 3H), 2.37 (s, 3H), 2.80 (s, 3H), 2.92 
(sept, 3JH−H = 6.8 Hz, 1H), 4.50 (d, 
3JH−H = 5.9 Hz, 1H), 5.03 (d, 
3JH−H = 5.9 Hz, 1H), 5.18 (d, 
3JH−H = 5.9 Hz, 1H), 5.48 (d, 
3JH−H = 5.9 Hz, 1H), 7.37 (m, 2H), 7.52 (d, 
3JH−H = 7.4 Hz, 1H), 
7.70 (s, 1H), 8.34 (s, 1H), 12.69 (s, 1H) ppm. ESI-MS m/z (+): 564.0 [M-Cl]+. Anal. Calcd for 
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C23H26N3OSCl3Ru: C, 46.05; H, 4.37; N, 7.00. Found: C, 45.89; H, 4.32; N, 6.98. IR (KBr): 
2963 (w), 1638 (m), 1560 (s), 1475 (m), 1374 (m), 1308 (s), 1079 (w) cm−1. 
15: [(η6-p-MeC6H4Pri)Ru(L14)Cl]Cl. Yield: 81%. 1H NMR (CDCl3, 400 MHz): δ = 0.98 (d, 
3JH−H = 6.8 Hz, 3H), 1.03 (d, 
3JH−H = 6.8 Hz, 3H), 2.18 (s, 3H), 2.40 (sept, 
3JH−H = 6.8 Hz, 1H), 
4.02 (d, 3JH−H = 5.9 Hz, 1H), 4.42 (d, 
3JH−H = 5.9 Hz, 1H), 4.69 (d, 
3JH−H = 5.9 Hz, 1H), 4.78 
(d, 3JH−H = 5.9 Hz, 1H), 6.77 (s, 1H), 7.54 (m, 5H), 7.90 (m, 3H), 8.50 (s, 1H), 9.27 (s, 1H), 
16.05 (s, 1H) ppm. ESI-MS m/z (+): 584.0 [M-Cl]+. Anal. Calcd for C26H26N3SCl3Ru·1.5 
H2O: C, 48.27; H, 4.52; N, 6.49. Found: C, 48.23; H, 4.01; N, 6.32. IR (KBr): 2969 (w), 2478 
(m), 1578 (s), 1499 (m), 1379 (w), 1325 (w), 1257 (w), 1088 (m) cm−1. 
16: [(η6-p-MeC6H4Pri)Ru(L16)Cl]Cl. Yield: 72%. 1H NMR (CDCl3, 400 MHz): δ = 1.08 (d, 
3JH−H = 6.2 Hz, 3H), 1.17 (d, 
3JH−H = 6.2 Hz, 3H), 1.34 (t, 
3JH−H = 7.2 Hz, 3H), 2.32 (s, 3H), 
2.60 (sept, 3JH−H = 6.2 Hz, 1H) 2.82 (s, 3H), 4.31 (q, 
3JH−H = 7.2 Hz, 2H), 4.61 (d, 
3JH−H = 5.3 
Hz, 1H), 5.15 (d, 3JH−H = 5.3 Hz, 1H), 5.24 (d, 
3JH−H = 5.3 Hz, 1H), 5.47 (d, 
3JH−H = 5.3 Hz, 
1H), 7.56 (m, 2H), 7.93 (m, 1H), 8.46 (s, 1H), 9.32 (s, 1H), 12.68 (s, 1H) ppm. ESI-MS m/z 
(+): 593.9 [M-Cl]+. Anal. Calcd for C24H28N3O2SCl3Ru·1.5 H2O: C, 43.88; H, 4.76; N, 6.40. 
Found: C, 43.76; H, 4.46; N, 5.88. IR (KBr): 2965 (w), 1711 (m), 1574 (s), 1475 (s), 1372 
(m), 1316 (s), 1276 (s), 1100 (s) cm−1. 
17: [(η6-p-MeC6H4Pri)Ru(L17)Cl]Cl. Yield: 63%. 1H NMR (CDCl3, 400 MHz): δ = 1.31 (d, 
3JH−H = 6.8 Hz, 6H), 1.33 (t, 
3JH−H = 7.0 Hz, 3H), 2.19 (s, 3H), 2.96 (sept, 
3JH−H = 6.8 Hz, 1H), 
4.30 (q, 3JH−H = 7.0 Hz, 2H), 5.38 (d, 
3JH−H = 5.8 Hz, 2H), 5.52 (d, 
3JH−H = 5.8 Hz, 2H), 7.43 
(m, 4H), 7.55 (s, 1H), 7.80 (d, 3JH−H = 7.2 Hz, 2H), 7.92 (d, 
3JH−H = 8.4 Hz, 1H), 8.22 (s, 1H), 
11.28 (s, 1H) ppm. ESI-MS m/z (+): 690.0 [M-Cl]+. Anal. Calcd for 
C29H29N3O2SCl4Ru·0.5CH2Cl2: C, 46.08; H, 3.93; N, 5.46. Found: C, 45.67; H, 3.75; N, 5.59. 
IR (KBr): 2969 (m), 1703 (m), 1675 (m), 1538 (m), 1488 (s), 1336 (s), 1300 (m), 1145 (s), 
1078 (m), 1014 (m), 754 (w) cm-1. 
18: [(η6-p-MeC6H4Pri)Ru(L18)Cl]Cl. Yield: 54%. 1H NMR (CDCl3, 400 MHz): δ = 1.30 (t, 
3JH−H = 7.2 Hz, 3H), 1.35 (d, 
3JH−H = 6.9 Hz, 6H), 2.32 (s, 3H), 3.11 (sept, 
3JH−H = 6.9 Hz, 1H), 
4.29 (q, 3JH−H = 7.2 Hz, 2H), 5.32 (d, 
3JH−H = 5.8 Hz, 2H), 5.52 (d, 
3JH−H = 5.8 Hz, 2H), 7.36 (t, 
3JH−H = 7.6 Hz, 1H), 7.47 (m, 5H), 7.73 (s, 1H), 7.79 (d, 
3JH−H = 7.6 Hz, 2H), 8.74 (s, 1H), 
12.58 (s, 1H) ppm. ESI-MS m/z (+): 656.1 [M-Cl]+. Anal. Calcd for 
C29H30N3O2SCl3Ru·0.5CH2Cl2: C, 48.24; H, 4.25; N, 5.72. Found: C, 48.01; H, 4.24; N, 5.34. 
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IR (KBr): 2968 (m), 1698 (m), 1538 (m), 1486 (s), 1336 (s), 1300 (m), 1147 (m), 1079 (m), 
755 (w) cm-1. 
19: [(η6-p-MeC6H4Pri)Ru(L19)Cl]Cl. Yield: 75%. 1H NMR (CDCl3, 400 MHz): δ = 1.02 (d, 
3JH−H = 6.6 Hz, 3H), 1.07 (d, 
3JH−H = 6.6 Hz, 3H), 1.52 (t, 
3JH−H = 7.0 Hz, 3H), 2.25 (s, 3H), 
2.50 (sept, 3JH−H = 6.6 Hz, 1H), 4.03 (q, 
3JH−H = 7.0 Hz, 2H), 4.05 (d, 
3JH−H = 5.7 Hz, 1H), 
4.75 (d, 3JH−H = 5.7 Hz, 1H), 4.82 (d, 
3JH−H = 5.7 Hz, 1H), 4.86 (d, 
3JH−H = 5.7 Hz, 1H), 6.76 (s, 
1H), 6.98 (m, 3H), 7.20 (m, 2H), 7.58 (m, 3H), 7.83 (m, 1H), 7.97 (m, 2H), 8.32 (s, 1H), 9.14 
(s, 1H), 15.35 (s, 1H) ppm. ESI-MS m/z (+): 699.1 [M-Cl]+. Anal. Calcd for 
C34H34N4S2Cl2Ru·0.5CH2Cl2: C, 53.32; H, 4.54; N, 7.21. Found: C, 53.35; H, 4.57; N, 6.54. 
IR (KBr): 2918 (m), 1575 (m), 1466 (s), 1384 (m), 1243 (m), 1053 (w), 752 (w) cm-1. 
20: [(η6-p-MeC6H4Pri)Ru(L20)Cl]Cl. Yield: 77%. 1H NMR (CDCl3, 400 MHz): δ = 1.12 (d, 
3JH−H = 6.7 Hz, 3H), 1.21 (d, 
3JH−H = 6.7 Hz, 3H), 1.52 (t, 
3JH−H = 6.8 Hz, 3H), 2.35 (s, 3H), 
2.46 (s, 3H), 2.86 (s, 3H), 3.18 (sept, 3JH−H = 6.7 Hz, 1H), 4.03 (q, 
3JH−H = 6.8 Hz, 2H), 4.94 
(d, 3JH−H = 5.9 Hz, 1H), 5.27 (d, 
3JH−H = 5.9 Hz, 1H), 5.47 (d, 
3JH−H = 5.9 Hz, 1H), 5.58 (d, 
3JH−H = 5.9 Hz, 1H), 6.97 (m, 4H), 7.18 (m, 3H), 7.86 (s, 1H), 8.25 (s, 1H), 9.06 (s, 1H), 14.69 
(s, 1H) ppm. ESI-MS m/z (+): 679.1 [M-Cl]+. Anal. Calcd for C31H34N4OS2Cl2Ru·CH2Cl2: C, 
48.06; H, 4.54; N, 7.01. Found: C, 47.29; H, 4.56; N, 6.95. IR (KBr): 2921 (m), 1624 (s), 
1468 (s), 1245 (m), 1110 (m), 751 (m) cm-1. 
21: [(η6-p-MeC6H4Pri)Ru(L21)Cl]Cl. Yield: 68%. 1H NMR (CDCl3, 400 MHz): δ = 1.08 (d, 
3JH−H = 6.5 Hz, 3H), 1.18 (d, 
3JH−H = 6.5 Hz, 3H), 1.48 (t, 
3JH−H = 6.7 Hz, 3H), 2.34 (s, 3H), 
2.46 (s, 3H), 2.65 (sept, 3JH−H = 6.5 Hz, 1H), 3.99 (q, 
3JH−H = 6.7, 2H), 4.93 (d, 
3JH−H = 5.6 Hz, 
1H), 5.22 (m, 2H), 5.47 (d, 3JH−H = 5.6 Hz, 1H), 6.46 (s, 1H), 6.95 (m, 3H), 7.16 (m, 2H), 7.78 
(m, 1H), 8.25 (s, 1H), 9.11 (s, 1H), 15.02 (s, 1H) ppm. ESI-MS m/z (+): 637.1 [M-Cl]+. Anal. 
Calcd for C29H32N4S2Cl2Ru·0.5CH2Cl2: C, 49.54; H, 4.65; N, 7.83. Found: C, 48.92; H, 4.76; 
N, 8.17. IR (KBr): 2921 (m), 1623 (s), 1466 (s), 1242 (m), 1136 (m), 753 (m) cm-1. 
22: [(η6-p-MeC6H4Pri)Ru(L22)Cl]Cl. Yield: 82%. 1H NMR (CDCl3, 400 MHz): δ = 1.09 (d, 
3JH−H = 6.7 Hz, 3H), 1.18 (d, 
3JH−H = 6.7 Hz, 3H), 1.33 (t, 
3JH−H = 7.1 Hz, 3H), 1.49 (t, 
3JH−H = 
6.9 Hz, 3H), 2.37 (s, 3H), 2.62 (sept, 3JH−H = 6.7 Hz, 1H), 2.82 (s, 3H), 4.00 (q, 
3JH−H = 6.9 Hz, 
2H), 4.30 (q, 3JH−H = 7.1 Hz, 2H), 4.93 (d, 
3JH−H = 5.6 Hz, 1H), 5.24 (m, 2H), 5.47 (d, 
3JH−H = 
5.6 Hz, 1H), 6.96 (m, 3H), 7.14 (d, 3JH−H = 7.4 Hz, 1H), 7.19 (t, 
3JH−H = 7.4 Hz, 1H), 7.76 (m, 
1H), 8.25 (s, 1H), 9.08 (s, 1H), 15.92 (s, 1H) ppm. ESI-MS m/z (+): 709.1 [M-Cl]+. Anal. 
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Calcd for C32H36N4O2S2Cl2Ru·CH2Cl2: C, 47.77; H, 4.62; N, 6.75. Found: C, 48.41; H, 4.87; 
N, 7.19. IR (KBr): 2969 (m), 1599 (s), 1465 (s), 1372 (m), 1271 (m), 1098 (s), 753 (m) cm-1. 
23: [(η6-p-MeC6H4Pri)Ru(L23)Cl]Cl. Yield:  70%. 1H NMR (CDCl3, 400 MHz): δ = 1.03 (d, 
3JH−H = 6.7 Hz, 3H), 1.09 (d, 
3JH−H = 6.7 Hz, 3H), 2.21 (s, 3H), 2.46 (s, 3H), 2.51 (sept, 
3JH−H 
= 6.7 Hz, 1H), 4.59 (d, 3JH−H = 5.3 Hz, 1H), 4.97 (d, 
3JH−H = 5.3 Hz, 1H), 5.10 (d, 
3JH−H = 5.3 
Hz, 1H), 5.37 (d, 3JH−H = 5.3 Hz, 1H), 6.45 (s, 1H), 6.54 (d, 
3JH−H = 2.7 Hz, 1H), 7.35 (d, 
3JH−H 
= 2.7 Hz, 1H), 7.50 (m, 2H), 8.07 (m, 1H), 8.92 (s, 1H), 10.25 (s, 1H) ppm. ESI-MS m/z (+): 
527.1 [M-Cl]+. Anal. Calcd for C23H26N4SCl2Ru·1.5CH2Cl2: C, 42.65; H, 4.24; N, 8.12. 
Found: C, 42.94; H, 4.23; N, 8.30. IR (KBr): 3421 (s), 2928 (m), 1617 (m), 1384 (m), 1060 
(m), 736 (m) cm-1. 
24: [(η6-p-MeC6H4Pri)Ru(L24)Cl]Cl. Yield:  64%. 1H NMR (CDCl3, 400 MHz): δ = 1.11 (d, 
3JH−H = 6.9 Hz, 3H), 1.16 (d, 
3JH−H = 6.9 Hz, 3H), 2.31 (s, 3H), 2.46 (s, 3H), 2.56 (sept, 
3JH−H 
= 6.9 Hz, 1H), 2.87 (s, 3H), 4.58 (d, 3JH−H = 6.0 Hz, 1H), 5.07 (d, 
3JH−H = 6.0 Hz, 1H), 5.20 (d, 
3JH−H = 6.0 Hz, 1H), 5.40 (d, 
3JH−H = 6.0 Hz, 1H), 6.71 (d, 
3JH−H = 2.8 Hz, 1H), 7.39 (t, 
3JH−H = 
2.8 Hz, 1H), 7.57 (d, 3JH−H = 2.8 Hz, 1H), 7.84 (d, J = 2.8 Hz, 1H), 8.42 (s, 1H), 9.08 (s, 1H) 
ppm. ESI-MS m/z (+): 569.1 [M-Cl]+. Anal. Calcd for C25H28N4OSCl2Ru·H2O: C, 48.23; H, 
4.86; N, 9.00. Found: C, 48.62; H, 4.80; N, 8.44. IR (KBr): 3430 (s), 2927 (m), 1614 (m), 
1571 (s), 1511 (s), 1375 (m), 1312 (s), 734 (m) cm-1. 
25: [(η6-p-MeC6H4Pri)Ru(L25)Cl]Cl. Yield:  71%. 1H NMR (CDCl3, 400 MHz): δ = 1.47 (d, 
3JH−H = 6.9 Hz, 6H), 2.41 (s, 3H), 3.25 (sept, 
3JH−H = 6.9 Hz, 1H), 5.40 (d, 
3JH−H = 5.6 Hz, 2H), 
5.63 (d, 3JH−H = 5.6 Hz, 2H), 6.67 (s, 1H), 7.46-7.52 (m, 7H), 7.68 (d, 
3JH−H = 8.5 Hz, 1H), 
7.81 (d, 3JH−H = 7.1 Hz, 2H), 7.96 (s, 1H), 8.41 (s, 1H) ppm. ESI-MS m/z (+): 589.1 [M-Cl]
+. 
Anal. Calcd for C28H28N4SCl2Ru·2CH2Cl2: C, 45.36; H, 4.06; N, 7.05. Found: C, 45.84; H, 
3.85; N, 7.63. IR (KBr): 2923 (m), 1623 (s), 1384 (m), 1349 (m), 1297 (w), 1124 (w), 729 (m) 
cm-1. 
26: [(η6-p-MeC6H4Pri)Ru(L26)Cl]Cl. Yield:  62%. 1H NMR (CDCl3, 400 MHz): δ = 1.05 (d, 
3JH−H = 6.8 Hz, 3H), 1.10 (d, 
3JH−H = 6.8 Hz, 3H), 1.37 (t, 
3JH−H = 7.1 Hz, 3H), 2.22 (s, 3H), 
2.55 (sept, 3JH−H = 6.8 Hz, 1H), 3.86 (d, 
2JH−H = -13.4 Hz, 2H), 4.30 (q, 
3JH−H = 7.1 Hz, 2H), 
4.67 (d, 3JH−H = 5.8 Hz, 1H), 5.02 (d, 
3JH−H = 5.8 Hz, 1H), 5.15 (d, 
3JH−H = 5.8 Hz, 1H), 5.51 
(d, 3JH−H = 5.8 Hz, 1H), 6.55 (d, 
3JH−H = 2.8 Hz, 1H), 6.77 (s, 1H), 7.34 (d, 
3JH−H = 2.8 Hz, 
1H), 7.50 (m, 2H), 8.08 (s, 1H), 8.94 (s, 1H), 10.04 (s, 1H) ppm. ESI-MS m/z (+): 599.1 [M-
Cl]+. Anal. Calcd for C26H30N4O2SCl2Ru·CH2Cl2: C, 45.07; H, 4.48; N, 7.79. Found: C, 
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45.12; H, 4.46; N, 7.79. IR (KBr): 2926 (m), 1731 (m), 1615 (s), 1579 (m), 1384 (m), 1350 
(m), 1255 (m), 1133 (m), 735 (m) cm-1. 
27: [(η6-p-MeC6H4Pri)Ru(L27)Cl]Cl. Yield:  76%. 1H NMR (CDCl3, 400 MHz): δ = 1.40 (d, 
3JH−H = 7.0 Hz, 6H), 2.34 (s, 3H), 2.67 (s, 3H), 2.78 (s, 3H), 3.16 (sept, 
3JH−H = 7.0 Hz, 1H), 
5.34 (d, 3JH−H = 5.9 Hz, 2H), 5.57 (d, 
3JH−H = 5.9 Hz, 2H), 6.14 (s, 1H), 7.73 (s, 1H), 8.14 (d, 
3JH−H = 7.8 Hz, 1H), 8.45 (d, 
3JH−H = 7.8 Hz, 1H), 8.51 (d, 
3JH−H = 7.8 Hz, 1H), 8.67 (s, 1H), 
8.99 (s, 1H), 9.44 (s, 1H) ppm. ESI-MS m/z (+): 569.1 [M-Cl]+. Anal. Calcd for 
C25H28N4OSCl2Ru·0.5CH2Cl2: C, 47.34; H, 4.52; N, 8.66. Found: C, 46.79; H, 4.68; N, 8.44. 
IR (KBr): 2924 (m), 1711 (m), 1631 (s), 1448 (m), 1377 (m), 1217 (s), 746 (m) cm-1. 
28: [(η6-p-MeC6H4Pri)Ru(L28)Cl]Cl. Yield:  66%. 1H NMR (CDCl3, 400 MHz): δ = 1.01 (d, 
3JH−H = 7.0 Hz, 3H), 1.06 (d, 
3JH−H = 7.0 Hz, 3H), 2.16 (s, 3H), 2.45 (sept, 
3JH−H = 7.0 Hz, 1H), 
2.84 (s, 3H), 5.39 (d, 3JH−H = 5.9 Hz, 1H), 5.41 (d, 
3JH−H = 5.9 Hz, 1H), 5.52 (d, 
3JH−H = 5.9 Hz, 
1H), 5.62 (d, 3JH−H = 5.9 Hz, 1H), 6.82 (s, 1H), 7.69 (s, 1H), 7.84 (d, 
3JH−H = 7.5 Hz, 2H), 7.99 
(m, 2H), 8.29 (d, 3JH−H = 7.5 Hz, 2H), 8.49-8.57 (m, 4H), 9.12 (s, 1H) ppm. ESI-MS m/z (+): 
631.1 [M-Cl]+. Anal. Calcd for C30H30N4OSCl2Ru·H2O: C, 52.63; H, 4.71; N, 8.18. Found: C, 
53.01; H, 4.45; N, 8.19. IR (KBr): 2926 (m), 1717 (s), 1623 (s), 1567 (s), 1450 (s), 1219 (s), 
753 (m) cm-1. 
29: [(η6-p-MeC6H4Pri)Ru(L29)Cl]Cl. Yield:  70%. 1H NMR (CDCl3, 400 MHz): δ = 1.32 (d, 
3JH−H = 7.0 Hz, 6H), 2.20 (s, 3H), 2.56 (s, 3H), 2.71 (s, 3H), 2.72 (s, 3H), 2.97 (sept, 
3JH−H = 
7.0 Hz, 1H), 5.39 (d, 3JH−H = 6.0 Hz, 2H), 5.52 (d, 
3JH−H = 6.0 Hz, 2H), 7.50 (m, 2H), 7.75 (s, 
1H), 8.28 (t, 3JH−H = 5.1 Hz, 1H), 8.40 (s, 1H), 8.48 (t, 
3JH−H = 5.1 Hz, 1H) ppm. ESI-MS m/z 
(+): 611.1 [M-Cl]+. Anal. Calcd for C27H30N4O2SCl2Ru·0.5CH2Cl2: C, 47.94; H, 4.53; N, 
8.13. Found: C, 48.45; H, 4.68; N, 7.79. IR (KBr): 2929 (m), 1718 (m), 1624 (s), 1567 (m), 
1450 (s), 1371 (s), 1327 (m), 1218 (s), 1033 (m), 752 (m) cm-1.  
30: [(η6-p-MeC6H4Pri)Ru(L30)Cl]Cl. Yield:  79%. 1H NMR (CDCl3, 400 MHz): δ = 1.28 (d, 
3JH−H = 7.1 Hz, 3H), 1.33 (d, 
3JH−H = 7.1 Hz, 3H), 1.40 (t, 
3JH−H = 7.1 Hz, 3H), 2.35 (s, 3H), 
2.68 (s, 3H), 2.79 (s, 3H), 3.14 (sept, 3JH−H = 7.1 Hz, 1H), 4.35 (q, 
3JH−H = 7.1 Hz, 2H), 5.36 
(d, 3JH−H = 6.3 Hz, 2H), 5.59 (d, 
3JH−H = 6.3 Hz, 2H), 7.45 (m, 2H), 7.71 (s, 1H), 8.22 (m, 1H), 
8.45 (m, 2H), 9.71 (s, 1H) ppm. ESI-MS m/z (+): 641.1 [M-Cl]+. Anal. Calcd for 
C28H32N4O3SCl2Ru·0.5CH2Cl2: C, 47.60; H, 4.63; N, 7.79. Found: C, 47.64; H, 4.53; N, 8.31. 
IR (KBr): 2930 (m), 1700 (s), 1616 (m), 1560 (s), 1450 (s), 1372 (s), 1218 (s), 1092 (s), 757 
(m) cm-1. 
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31: [(η6-p-MeC6H4Pri)Ru(L31)Cl]Cl. Yield:  82%. 1H NMR (CDCl3, 400 MHz): δ = 1.12 (d, 
3JH−H = 6.8 Hz, 3H), 1.23 (d, 
3JH−H = 6.8 Hz, 3H), 1.41 (t, 
3JH−H = 7.2 Hz, 3H), 2.31 (s, 3H), 
2.69 (sept, 3JH−H = 6.8 Hz, 1H), 2.83 (s, 3H), 3.91 (d, 
2JH−H = -13.7 Hz, 2H), 4.35 (q, 
3JH−H = 
7.2 Hz, 2H), 4.84 (d, 3JH−H = 5.8 Hz, 1H), 5.33 (d, 
3JH−H = 5.8 Hz, 1H), 5.37 (d, 
3JH−H = 5.8 Hz, 
1H), 5.65 (d, 3JH−H = 5.8 Hz, 1H), 6.84 (s, 1H), 7.49-7.56 (m, 3H), 7.92 (m, 1H), 8.57 (d, 
3JH−H = 8.0 Hz, 1H), 9.07 (s, 1H), 9.40 (s, 1H) ppm. ESI-MS m/z (+): 641.1 [M-Cl]+. Anal. 
Calcd for C28H32N4O3SCl2Ru: C, 49.70; H, 4.77; N, 8.28. Found: C, 49.97; H, 5.12; N, 8.47. 
IR (KBr): 2929 (m), 1722 (s), 1617 (m), 1576 (m), 1547 (m), 1451 (s), 1379 (s), 1217 (s), 754 
(m) cm-1. 
 
5.2.2 Light-Responsive Ruthenium Assemblies 
Synthesis of ruthenium-azopyridine rectangles 32-35: A mixture of the dinuclear ruthenium 
spacer (1 equivalent) and silver trifluoromethanesulfonate (2 equivalents) in dichloromethane 
was stirred at room temperature for 3 hours. The resulting mixture was filtrated in order to 
eliminate the silver chloride formed, and the solution was added to a solution of 4,4’-
azopyridine (1 equivalent) in dichloromethane. The mixture was then refluxed overnight, and 
consequently concentrated under vacuum. The residue was dissolved in a few milliliters of 
dichloromethane, and slow addition of diethyl ether induced the precipitation of the rectangles, 
which were then filtered and dried under vacuum. 
33: Yield: 61%. 1H NMR (CD3NO2, 400 MHz): δ = 1.44 (d, 3JH−H = 7.1 Hz, 24H), 2.33 (s, 
12H), 2.99 (sept, 3JH−H = 7.1 Hz, 4H), 5.90 (d, 
3JH−H = 6.3 Hz, 8H), 6.07 (d, 
3JH−H = 6.3 Hz, 
8H), 7.85 (d, 3JH−H = 6.8 Hz, 8H), 8.63 (d, 
3JH−H = 6.8 Hz, 8H) ppm. ESI-MS m/z (+): 1009.8 
[M-2OTf]2+. IR (KBr): 2969 (m), 1606 (m), 1505 (s), 1374 (s), 1260 (s), 1159 (s), 1030 (s), 
866 (m), 638 (s) cm-1. UV-visible (CH2Cl2, C = 6.0 x 10
-6 mol·L-1): λmax = 307 nm (ε = 3.50 x 
105 L·mol-1·cm-1), 489 nm (ε = 2.15 x 105 L·mol-1·cm-1). 
Synthesis of anthracene-based ligand L36:  A mixture of 9,10-dibromoanthracene (1 
equivalent) and 3-ethynylpyridine (2.2 equivalents) was dissolved in a 1:1 triethylamine-
toluene solution under nitrogen. A mixture of palladium (II) acetate (0.02 equivalent), copper 
(I) iodide (0.025 equivalent) and triphenylphosphine (0.055 equivalent) was then added. The 
reaction medium was refluxed for 24 hours; the solvent was then removed under vacuum and 
the residue was stirred in water for two hours in order to eliminate the triethylammonium salt. 
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The solid was filtered and dried under vacuum, and finally recrystallized in toluene to yield 
L36 as an orange powder. 
L36: Yield: 57%. 1H NMR (CDCl3, 400 MHz): δ = 7.41 (m, 2H), 7.68 (dd, 3JH−H = 6.6 Hz, 
4JH−H = 3.3 Hz, 4H), 8.05 (d, 
3JH−H = 7.7 Hz, 2H), 8.66 (m, 6H), 9.02 (s, 2H) ppm.
 
Synthesis of ruthenium-anthracene rectangle 36: A mixture of [(η6-p-
MeC6H4Pr
i)2Ru2(oxa)Cl2] (1 equivalent) and silver trifluoromethanesulfonate (2 equivalents) 
in dichloromethane was stirred at room temperature for 3 hours. The resulting mixture was 
filtrated in order to eliminate the silver chloride formed, and the solution was added to a 
solution of L36 (1 equivalent) in dichloromethane. The mixture was then refluxed overnight, 
and consequently concentrated under vacuum. The residue was dissolved in a few milliliters 
of dichloromethane, and slow addition of diethyl ether induced the precipitation of 36 as a 
yellow powder, which was then filtered and dried under vacuum. 
36: Yield: 83%. 1H NMR (Acetone-d6, 400 MHz): δ = 1.44 (d, 3JH−H = 7.0 Hz, 12H), 1.47 (d, 
3JH−H = 7.0 Hz, 12H), 2.38 (s, 12H), 3.05 (sept, 
3JH−H = 7.0 Hz, 4H), 6.05 (d, 
3JH−H = 6.1 Hz, 
4H), 6.08 (d, 3JH−H = 6.1 Hz, 4H), 6.20 (d, 
3JH−H = 6.1 Hz, 4H), 6.23 (d, 
3JH−H = 6.1 Hz, 4H), 
7.36 (m, 8H), 7.66 (t, 3JH−H = 6.8 Hz, 4H), 8.18 (m, 12H), 8.65 (m, 8H) ppm. 
13C NMR 
(Acetone-d6, 400 MHz): δ = 17.26, 21.40, 21.74, 31.01, 81.39, 82.20, 91.95, 96.46, 97.99, 
102.54, 116.94, 119.97, 122.84, 123.17, 126.24, 126.70, 127.20, 130.89, 142.83, 151.62, 
153.70, 171.10, 171.23 ppm. ESI-MS m/z (+): 469.6 [M-4OTf]4+, 675.7 [M-3OTf]3+, 1088.8 
[M-2OTf]2+. Anal. Calcd for C104H88N4O20S4F12Ru4: C, 50.48; H, 3.58; N, 2.26. Found: C, 
50.64; H, 3.84; N, 2.17. IR (KBr): 2927 (w), 2208 (w), 1624 (s), 1417 (m), 1262 (s), 1195 (m), 
1149 (m), 1058 (s), 1030 (s), 883 (w), 769 (m) cm-1. UV-visible (CH2Cl2, C = 1.0 x 10
-5 
mol·L-1): λmax = 247 nm (ε = 7.88 x 105 L·mol-1·cm-1), 272 nm (ε = 7.94 x 105 L·mol-1·cm-1), 
306 nm (ε = 5.45 x 105 L·mol-1·cm-1), 457 nm (ε = 6.43 x 105 L·mol-1·cm-1), 488 nm (ε = 3.90 
x 105 L·mol-1·cm-1). 
Synthesis of ruthenium-anthracene cage 37: A mixture of [(η6-p-MeC6H4Pri)2Ru2(dhnq)Cl2] 
(2 equivalents) and silver trifluoromethanesulfonate (4 equivalents) in dichloromethane was 
stirred at room temperature for 3 hours. The resulting mixture was filtrated in order to 
eliminate the silver chloride formed, and the solution was added to a solution of L37 (1 
equivalent) in dichloromethane. The mixture was then refluxed overnight, and consequently 
concentrated under vacuum. The residue was dissolved in a few milliliters of dichloromethane, 
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and slow addition of diethyl ether induced the precipitation of 37 as a green powder, which 
was then filtered and dried under vacuum. 
37: Yield: 73%. 1H NMR (Acetone-d6, 400 MHz): δ = 1.37 (d, 3JH−H = 6.9 Hz, 24H), 1.43 (d, 
3JH−H = 6.9 Hz, 24H), 2.21 (s, 12H), 2.24 (s, 12H), 2.31 (s, 12H), 2.96 (sept, 
3JH−H = 6.9 Hz, 
8H), 3.65 (s, 12H), 5.83 (d, 3JH−H = 5.6 Hz, 16H), 6.04 (d, 
3JH−H = 5.6 Hz, 16H), 6.14 (s, 4H), 
6.91 (s, 4H), 7.28 (d, 3JH−H = 2.1 Hz, 8H), 7.39 (d, 
3JH−H = 2.1 Hz, 8H), 7.94 (s, 4H), 8.12 (d, 
3JH−H = 6.1 Hz, 8H), 8.13 (s, 4H), 8.30 (d, 
3JH−H = 6.1 Hz, 8H), 8.60 (d, 
3JH−H = 6.1 Hz, 8H), 
8.68 (s, 4H), 8.70 (d, 3JH−H = 6.1 Hz, 8H) ppm. 
13C NMR (Acetone-d6, 400 MHz): δ = 16.88, 
21.95, 31.09, 54.10, 55.35, 83.45, 85.02, 100.22, 103.12, 103.73, 104.30, 123.65, 124.93, 
125.97, 131.92, 132.21, 136.50, 138.13, 148.73, 150.14, 153.18, 171.39 ppm. ESI-MS m/z 
(+): 1187.64 [M-4OTf]4+, 1633.25 [M-3OTf]3+. Anal. Calcd for C228H204N8O48S8F24Ru8·2 
CH2Cl2: C, 50.09; H, 3.80; N, 2.03. Found: C, 49.73; H, 3.93; N, 1.77. IR (KBr): 2929 (w), 
1611 (w), 1538 (s), 1274 (s), 1031 (m) cm-1. UV-visible (CH2Cl2, C = 4.7 x 10
-7 mol·L-1): 
λmax = 279 nm (ε = 1.11 x 106 L·mol-1·cm-1), 303 nm (ε = 4.88 x 105 L·mol-1·cm-1), 377 nm (ε 
= 2.01 x 105 L·mol-1·cm-1). 
Multi-step synthesis of dihydropyrene precursor DHP: 
Step i): synthesis of a: A mixture of 4-tert-butyltoluene (1 equivalent), 1,3,5-trioxane (0.9 
equivalent), zinc (II) bromide (0.1 equivalent) in hydrobromic acid (33% in acetic acid) and 
acetic anhydride was stirred at 85 °C for five days. Once back at room temperature, the 
mixture was poured onto ice. The resulting yellow precipitate was filtered, washed with water 
and a saturated solution of NaHCO3, and dried under vacuum. It was finally recrystallized in 
hexane in order to yield a white powder. 
Step ii): synthesis of b: Product a (1 equivalent) was added to a 40 °C solution of thiourea (2 
equivalents) in ethanol; the resulting mixture was refluxed for two hours. A solution of 
sodium hydroxide was then added under nitrogen and the refluxed was resumed for three 
more hours. The mixture was cooled in an ice bath, and cold concentrated sulfuric acid was 
gently added. The product was then extracted with diethyl ether, washed with water, and the 
solvent was removed under vacuum. Recrystallization of the crude product in hexane gave b 
as a white powder. 
Step iii): synthesis of c: A solution of a (1 equivalent) and b (1 equivalent) in dry benzene 
was added dropwise under nitrogen to a solution of potassium hydroxide and sodium 
Experimental Section 
80 
 
borohydride in ethanol. The drop rate was adjusted so that the addition lasted 24 hours. The 
solvents were then removed under vacuum, and the residue was dissolved in dichloromethane 
and washed with water. After removal of the solvent, the crude product was recrystallized in 
toluene to yield c as a white powder. 
Step iv): synthesis of d: To an ice-cooled solution of c (1 equivalent) in THF was slowly 
added n-butyllithium (3.9 equivalents) under nitrogen. After one hour of stirring at room 
temperature, methyl iodide (4 equivalents) was added, and the stirring was resumed for 
another 30 minutes. The mixture was then poured onto ice and the product was extracted with 
dichloromethane, washed with water, and the solvent was removed under vacuum to yield d 
as a yellow oil. 
Step v): synthesis of e: A solution of trimethyl orthoformate (3 equivalents) in dry 
dichloromethane was colled to -30 °C, after what boron trifluoride (3 equivalents) was added. 
The mixture was stirred at 0 °C for 30 minutes, cooled back to -30 °C, and washed with 
dichloromethane. To the resulting oily Borch reagent[81] was added a solution of d (1 
equivalent) in dichloromethane, at -30 °C and under nitrogen. The mixture was then stirred at 
room temperature for three hours, and washed with ethyl acetate for a further two hours. The 
product was then filtered and dried under vacuum to give e as a white powder. 
Step vi): synthesis of DHP: Potassium tert-butylate (2.7 equivalents) was added to a 
suspension of e (1 equivalent) in dry THF, and the mixture was refluxed for 12 hours under 
nitrogen. An aqueous solution of hydrochloric acid was added, and the product was extracted 
with dichloromethane and washed with water. After removal of the solvent under vacuum, the 
green residue was chromatographed over silica gel using hexane as eluent to yield DHP as a 
green powder. 
DHP: Yield (from tert-butyltoluene): 42%. 1H NMR (CDCl3, 400 MHz): δ = -4.04 (s, 6H), 
1.70 (s, 18H), 8.46 (s, 4H), 8.54 (s, 4H) ppm. 
Synthesis of brominated dihydropyrene intermediate DHP-Br: To an ice-cooled solution of 
DHP (1 equivalent) in dry DMF was added an ice-cooled solution of N-bromosuccinimide 
(2.1 equivalents). The mixture was stirred at 0 °C for two hours and was then poured onto ice. 
The product was extracted with hexane, washed with water, and the solvent was removed 
under vacuum. The crude product was then chromatographed over silica gel using hexane as 
eluent to yield DHP-Br as a green powder. 
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DHP-Br: Yield: 66%. 1H NMR (CDCl3, 400 MHz): δ = -3.83 (s, 6H), 1.68 (s, 18H), 8.48 (s, 
2H), 8.64 (s, 2H), 8.81 (s, 2H) ppm. 
Synthesis of dihydropyrene-based ligand L38: A solution of DHP-Br (1 equivalent) and 4-
pyridineboronic acid (2.2 equivalents) in THF was added to a solution of Pd(PPh3)4 (0.2 
equivalent) and Na2CO3 (4.75 equivalents) in water. The mixture was refluxed for 48 hours, 
after what the solvent was removed under vacuum. The residue was dissolved in water and 
the product was extracted with dichloromethane, then concentrated under vacuum. Slow 
addition of diethyl ether precipitated L38, which was filtered, dried under vacuum and 
isolated as a green powder. 
L38: Yield: 53%. 1H NMR (CDCl3, 400 MHz): δ = -3.68 (s, 6H), 1.61 (s, 18H), 7.78 (m, 4H), 
8.48 (s, 2H), 8.60 (s, 2H), 8.65 (s, 2H), 8.86 (m, 4H) ppm. 
Synthesis of ruthenium-dihydropyrene rectangle 38: A mixture of [(η6-p-
MeC6H4Pr
i)2Ru2(dhnq)Cl2] (1 equivalent) and silver trifluoromethanesulfonate (2 equivalents) 
in dichloromethane was stirred at room temperature for 3 hours. The resulting mixture was 
filtrated in order to eliminate the silver chloride formed, and the solution was added to a 
solution of L38 (1 equivalent) in dichloromethane. The mixture was then refluxed overnight, 
and consequently concentrated under vacuum. The residue was dissolved in a few milliliters 
of dichloromethane, and slow addition of diethyl ether induced the precipitation of 38 as a 
brown powder, which was then filtered and dried under vacuum. 
38: Yield: 38%. 1H NMR (Acetone-d6, 400 MHz): δ = -3.98 (s, 3H), -3.92 (s, 6H), -3.74 (s, 
3H), 1.17 (s, 18H), 1.20 (s, 9H), 1.33 (d, 3JH−H = 7.0 Hz, 12H), 1.37 (d, 
3JH−H = 7.0 Hz, 12H), 
1.54 (s, 9H), 2.32 (s, 12H), 3.03 (sept, 3JH−H = 7.0 Hz, 4H), 5.93 (d, 
3JH−H = 5.8 Hz, 8H), 6.12 
(d, 3JH−H = 5.8 Hz, 8H), 7.22 (s, 4H), 7.44 (s, 4H), 7.45 (s, 4H), 7.99 (d, 
3JH−H = 6.3 Hz, 8H), 
8.33 (s, 4H), 8.40 (s, 4H), 8.92 (d, 3JH−H = 6.3 Hz, 8H) ppm. 
13C NMR (Acetone-d6, 400 
MHz): δ = 14.66, 17.10, 22.00, 30.14, 31.12, 31.39, 36.28, 83.26, 84.94, 100.31, 103.89, 
119.91, 123.04, 124.63, 128.48, 130.57, 133.52, 138.01, 152.41, 170.88, 172.11 ppm. ESI-
MS m/z (+): 1306.9 [M-2OTf]2+. IR (KBr): 2964 (m), 1611 (m), 1536 (s), 1422 (m), 1275 (s), 
1159 (m), 1031 (s), 638 (m) cm-1. UV-visible (CH2Cl2, C = 1.0 x 10
-5 mol·L-1): λmax = 344 nm 
(ε = 8.39 x 105 L·mol-1·cm-1), 411 nm (ε = 9.32 x 105 L·mol-1·cm-1), 489 nm (ε = 3.25 x 105 
L·mol-1·cm-1). 
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